data_2mj1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mj1 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 N--CA 1.467 0.425 0 N-CA-C 111.554 0.205 . . . . 6.54 111.554 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.442 ' O ' HG23 ' A' ' 8' ' ' VAL . 7.6 t80 -60.98 -47.99 83.88 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 122.914 0.486 . . . . 6.2699999999999996 111.58 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.24 -27.13 65.48 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.095 0.558 . . . . 3.2599999999999998 112.145 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -92.65 -38.02 12.1 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.945 -0.57 . . . . 4.4900000000000002 110.323 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -70.87 -29.11 65.13 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 115.974 -0.557 . . . . 3.3700000000000001 112.482 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 4' ' ' PHE . 5.3 m -62.0 -23.35 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 112.883 0.697 . . . . 4.5999999999999996 112.883 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.21 -21.75 77.25 Favored Glycine 0 C--N 1.344 0.988 0 O-C-N 123.308 0.38 . . . . 2.0 113.532 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.589 ' O ' ' HB1' ' A' ' 14' ' ' ALA . 72.0 m -123.83 -50.22 1.84 Allowed 'General case' 0 C--O 1.245 0.853 0 CA-C-O 120.868 0.366 . . . . 3.8199999999999998 110.648 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.554 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.8 t30 45.66 -171.17 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.607 1.163 . . . . 4.8700000000000001 113.321 179.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.554 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.2 mptm? -47.33 -46.16 25.21 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.237 0.615 . . . . 5.4699999999999998 111.346 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.31 -45.95 57.76 Favored Glycine 0 C--N 1.35 1.322 0 O-C-N 124.258 0.974 . . . . 2.0499999999999998 114.201 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.589 ' HB1' ' O ' ' A' ' 10' ' ' SER . . . -89.71 -39.09 13.39 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-N 117.321 0.56 . . . . 2.2799999999999998 111.879 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.437 HG12 ' O ' ' A' ' 11' ' ' ASN . 3.3 pt -67.12 -25.83 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 N-CA-C 112.278 0.473 . . . . 3.8199999999999998 112.278 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.9 tp -80.72 -42.09 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.974 -0.38 . . . . 4.2699999999999996 109.974 178.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.52 -42.98 54.35 Favored Glycine 0 C--N 1.346 1.087 0 CA-C-N 115.701 -0.681 . . . . 2.1600000000000001 112.895 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.7 mt . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.152 -0.928 . . . . 5.0099999999999998 110.837 -179.917 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.483 ' O ' HG12 ' A' ' 8' ' ' VAL . 31.7 p90 -59.23 -43.37 92.37 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 112.392 0.515 . . . . 0.0 112.392 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.41 -28.34 53.53 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.142 0.577 . . . . 0.0 112.408 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -100.71 -35.75 9.36 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.131 178.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.89 -22.24 62.3 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.579 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 4' ' ' PHE . 1.8 m -56.09 -29.0 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.53 -13.46 71.23 Favored Glycine 0 C--N 1.342 0.913 0 O-C-N 123.244 0.34 . . . . 0.0 113.527 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 29.0 m -128.57 -57.32 1.2 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 122.649 0.38 . . . . 0.0 110.525 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 18.0 -120.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 125.704 1.602 . . . . 0.0 115.085 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.44 ' O ' HG23 ' A' ' 16' ' ' ILE . 8.5 tptm -59.67 -51.05 71.45 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.609 0.764 . . . . 0.0 112.479 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.13 -31.06 48.46 Favored Glycine 0 C--N 1.35 1.345 0 O-C-N 123.828 0.705 . . . . 0.0 113.839 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -93.22 -41.01 10.13 Favored 'General case' 0 C--O 1.24 0.576 0 O-C-N 123.634 0.255 . . . . 0.0 111.047 178.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -66.62 -30.28 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.345 0.403 . . . . 0.0 111.699 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.44 HG23 ' O ' ' A' ' 12' ' ' LYS . 3.4 tp -81.21 -40.8 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.785 0 O-C-N 123.201 0.313 . . . . 0.0 110.165 178.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.36 -41.83 57.97 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.936 178.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 mp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.836 -179.884 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.7 p90 . . . . . 0 N--CA 1.478 0.953 0 N-CA-C 111.589 0.218 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -60.3 -47.87 84.19 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 122.963 0.505 . . . . 0.0 112.041 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.18 -27.34 67.05 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -92.59 -42.81 9.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.677 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -70.93 -28.47 64.53 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.62 -23.86 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.38 -18.81 75.56 Favored Glycine 0 C--N 1.343 0.934 0 CA-C-O 119.895 -0.391 . . . . 0.0 113.881 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.4 m -133.53 -45.84 0.82 Allowed 'General case' 0 C--O 1.238 0.461 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.45 ' O ' ' HB ' ' A' ' 15' ' ' ILE . 3.0 t30 -57.97 -48.11 80.96 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.753 0.421 . . . . 0.0 111.752 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.486 ' O ' HG22 ' A' ' 15' ' ' ILE . 12.4 tptp -65.04 -50.48 66.05 Favored 'General case' 0 C--O 1.241 0.612 0 O-C-N 123.3 0.375 . . . . 0.0 110.095 179.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.95 -34.49 83.42 Favored Glycine 0 C--N 1.35 1.36 0 O-C-N 123.946 0.779 . . . . 0.0 112.498 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.36 -39.98 31.32 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 122.256 0.223 . . . . 0.0 110.634 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.486 HG22 ' O ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -68.47 -35.1 69.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.376 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -74.48 -43.89 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-O 120.623 0.249 . . . . 0.0 110.664 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.35 -42.38 56.92 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.009 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.587 -179.795 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 p90 . . . . . 0 CA--C 1.544 0.717 0 CA-C-O 120.893 0.378 . . . . 0.0 111.265 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -61.65 -39.93 93.09 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.113 0.565 . . . . 0.0 111.782 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.06 -31.19 68.65 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.891 0.477 . . . . 0.0 111.822 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -95.03 -34.59 12.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.263 178.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.401 ' O ' HG11 ' A' ' 8' ' ' VAL . 1.6 t70 -70.55 -26.78 63.71 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.834 179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.511 HG21 ' H ' ' A' ' 9' ' ' GLY . 3.9 p 52.58 -149.7 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 C-N-CA 124.289 1.036 . . . . 0.0 110.944 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.511 ' H ' HG21 ' A' ' 8' ' ' VAL . . . -59.54 -55.77 28.7 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 118.361 0.528 . . . . 0.0 113.244 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.4 m -152.78 45.21 0.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 122.419 0.288 . . . . 0.0 111.045 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.661 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.9 p-10 23.93 -100.85 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.661 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.0 OUTLIER -60.67 -53.81 52.86 Favored 'General case' 0 C--N 1.354 0.781 0 C-N-CA 123.226 0.61 . . . . 0.0 110.597 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.09 -27.93 63.21 Favored Glycine 0 C--N 1.349 1.276 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.609 178.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -80.41 -48.61 12.63 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 122.286 0.235 . . . . 0.0 110.674 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.508 HG13 ' O ' ' A' ' 12' ' ' LYS . 2.2 pp -66.74 -41.35 87.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.592 HG21 ' O ' ' A' ' 12' ' ' LYS . 3.3 tp -81.24 -35.1 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 178.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.13 -38.02 63.59 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.759 -0.655 . . . . 0.0 113.217 178.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.9 tt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.535 -179.87 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 . . . . . 0 N--CA 1.486 1.339 0 N-CA-C 112.47 0.545 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.491 ' O ' HG11 ' A' ' 8' ' ' VAL . 46.0 p90 -57.03 -45.78 82.87 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.53 -28.58 55.64 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -98.94 -39.37 8.6 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.081 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -70.81 -20.39 62.58 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.577 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 1.4 m -55.53 -31.51 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.59 -16.67 74.14 Favored Glycine 0 CA--C 1.529 0.945 0 O-C-N 123.411 0.444 . . . . 0.0 113.642 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.473 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 63.2 m -119.99 -56.35 2.02 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.484 0.314 . . . . 0.0 110.853 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.577 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER 43.34 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.756 1.222 . . . . 0.0 113.867 179.161 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.0 mmtp -50.81 -39.61 53.51 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 123.147 0.579 . . . . 0.0 111.457 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.65 -46.29 75.21 Favored Glycine 0 C--N 1.351 1.383 0 O-C-N 123.979 0.799 . . . . 0.0 113.259 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.473 ' HB2' ' O ' ' A' ' 10' ' ' SER . . . -87.82 -37.15 16.8 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.691 0.245 . . . . 0.0 110.927 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.7 mt -64.22 -27.75 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 123.205 0.316 . . . . 0.0 111.212 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 3.5 tp -79.93 -42.36 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.33 -43.98 53.22 Favored Glycine 0 C--N 1.345 1.051 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.989 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.6 tp . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.495 -0.764 . . . . 0.0 110.565 -179.907 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 . . . . . 0 N--CA 1.488 1.457 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.462 ' O ' ' HB ' ' A' ' 8' ' ' VAL . 9.7 t80 -70.79 -61.73 1.65 Allowed 'General case' 0 C--N 1.364 1.23 0 CA-C-N 118.764 0.711 . . . . 0.0 111.645 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -56.57 -22.26 32.27 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -99.22 -50.07 4.26 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 123.231 0.332 . . . . 0.0 110.949 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -71.02 -17.03 62.64 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 4' ' ' PHE . 11.1 p -58.78 -27.85 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.45 -13.99 71.51 Favored Glycine 0 C--N 1.344 0.973 0 O-C-N 123.329 0.393 . . . . 0.0 113.8 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 42.4 p -128.79 -24.87 2.91 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 122.404 0.282 . . . . 0.0 111.694 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.7 t30 -53.64 -50.99 64.56 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.127 0.571 . . . . 0.0 111.669 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.499 ' O ' HG13 ' A' ' 15' ' ' ILE . 34.1 mtmt -60.17 -53.08 61.94 Favored 'General case' 0 C--O 1.242 0.689 0 O-C-N 123.484 0.49 . . . . 0.0 110.327 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.92 -30.31 69.56 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.406 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.28 -44.66 24.81 Favored 'General case' 0 C--O 1.239 0.55 0 O-C-N 123.71 0.3 . . . . 0.0 111.146 178.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.3 pt -71.24 -34.48 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -71.8 -44.84 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 CA-C-O 120.767 0.318 . . . . 0.0 110.411 178.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.34 -45.17 49.47 Favored Glycine 0 C--N 1.346 1.107 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.842 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.169 0 C-N-CA 123.849 0.86 . . . . 0.0 111.814 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.52 ' HB3' ' OD2' ' A' ' 7' ' ' ASP . 88.3 m-85 . . . . . 0 N--CA 1.469 0.499 0 N-CA-C 111.625 0.232 . . . . 0.0 111.625 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -64.48 -47.6 78.37 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 122.843 0.457 . . . . 0.0 111.632 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.47 -25.15 64.17 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -97.53 -52.14 3.88 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.377 179.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.52 ' OD2' ' HB3' ' A' ' 3' ' ' PHE . 50.6 m-20 -71.4 -11.14 60.74 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.2 m 28.55 -120.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 178.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.17 -11.87 67.95 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.554 ' O ' ' HB1' ' A' ' 14' ' ' ALA . 70.1 m -81.06 -54.14 5.8 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 122.59 0.356 . . . . 0.0 110.326 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.625 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.3 t30 41.68 -166.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 124.282 1.033 . . . . 0.0 113.649 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.625 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 97.2 mttt -48.87 -43.6 39.06 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.066 0.546 . . . . 0.0 111.245 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -51.79 -40.03 48.37 Favored Glycine 0 C--N 1.355 1.62 0 O-C-N 124.309 1.006 . . . . 0.0 113.772 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.554 ' HB1' ' O ' ' A' ' 10' ' ' SER . . . -93.98 -34.78 12.92 Favored 'General case' 0 C--O 1.241 0.605 0 CA-C-N 116.847 0.323 . . . . 0.0 110.673 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.593 HG12 ' O ' ' A' ' 11' ' ' ASN . 46.2 mm -63.18 -33.39 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 CA-C-O 119.034 -0.507 . . . . 0.0 112.271 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.566 HG22 ' O ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -84.21 -35.11 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.458 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.46 ' H ' HD12 ' A' ' 16' ' ' ILE . . . -71.3 -43.03 56.03 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.925 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.935 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.489 ' HB2' ' OD2' ' A' ' 7' ' ' ASP . 40.0 p90 . . . . . 0 N--CA 1.473 0.689 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -58.01 -45.0 87.59 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 122.931 0.492 . . . . 0.0 112.221 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -58.1 -36.19 72.52 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.09 -37.95 13.89 Favored 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.432 0.457 . . . . 0.0 111.115 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.489 ' OD2' ' HB2' ' A' ' 3' ' ' PHE . 6.5 m-20 -70.72 -29.68 66.01 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.0 p -62.86 -28.54 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.57 -12.36 69.96 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.412 0.445 . . . . 0.0 113.876 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.7 t -130.64 -50.6 1.06 Allowed 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.778 0.289 . . . . 0.0 111.375 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -57.58 -51.2 70.44 Favored 'General case' 0 N--CA 1.475 0.813 0 O-C-N 123.276 0.36 . . . . 0.0 111.474 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.485 ' O ' HG13 ' A' ' 15' ' ' ILE . 12.1 tptm -60.19 -52.16 66.48 Favored 'General case' 0 C--O 1.242 0.673 0 O-C-N 123.498 0.499 . . . . 0.0 109.915 179.089 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.01 -31.69 73.34 Favored Glycine 0 C--N 1.35 1.327 0 O-C-N 124.013 0.821 . . . . 0.0 112.441 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.36 -44.87 27.89 Favored 'General case' 0 C--O 1.239 0.534 0 C-N-CA 122.324 0.25 . . . . 0.0 111.08 178.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.485 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.4 pt -70.92 -34.08 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -72.45 -44.67 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.403 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.65 -44.15 49.96 Favored Glycine 0 C--N 1.345 1.037 0 CA-C-N 115.487 -0.779 . . . . 0.0 112.86 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.84 -179.913 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . 0.43 ' CE2' ' HD2' ' A' ' 4' ' ' PHE . 3.1 t80 . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 119.603 -0.237 . . . . 0.0 111.556 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.43 ' HD2' ' CE2' ' A' ' 3' ' ' PHE . 87.9 m-85 -60.52 -57.9 10.78 Favored 'General case' 0 C--N 1.36 1.059 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.091 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.83 -25.68 30.05 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -101.69 -41.24 6.63 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 123.196 0.31 . . . . 0.0 111.54 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -70.26 -31.97 69.59 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.62 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 59.0 t -81.73 -27.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 123.16 0.287 . . . . 0.0 110.759 -179.153 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.43 -11.37 68.07 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 123.196 0.31 . . . . 0.0 113.019 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.641 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 67.3 m -128.33 -46.61 1.33 Allowed 'General case' 0 C--O 1.244 0.8 0 C-N-CA 122.843 0.457 . . . . 0.0 110.736 179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.62 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER 45.13 -169.12 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.472 1.109 . . . . 0.0 113.662 179.288 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.56 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 31.4 tttp -48.92 -45.98 42.31 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.521 0.728 . . . . 0.0 111.377 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.7 -47.1 65.51 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 114.979 -1.01 . . . . 0.0 114.271 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.641 ' HB2' ' O ' ' A' ' 10' ' ' SER . . . -88.53 -41.46 12.7 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 117.248 0.524 . . . . 0.0 111.735 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.3 tt -63.55 -30.2 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.56 ' HB ' ' O ' ' A' ' 12' ' ' LYS . 1.2 mp -92.3 -36.31 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -70.85 -29.1 69.67 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-N 115.896 -0.593 . . . . 0.0 113.412 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.083 -0.96 . . . . 0.0 110.656 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 18.9 p90 . . . . . 0 N--CA 1.471 0.607 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -65.28 -44.54 87.69 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.778 0.431 . . . . 0.0 111.58 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -65.61 -23.93 66.94 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.939 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -92.11 -44.57 8.75 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.335 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.477 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 3.1 t70 -70.92 -29.31 65.32 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.638 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 m 42.53 -153.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 124.646 1.178 . . . . 0.0 112.59 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 66.87 0.87 Allowed Glycine 0 C--N 1.352 1.453 0 C-N-CA 121.73 -0.272 . . . . 0.0 112.587 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 20.3 t 63.24 66.89 0.69 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.973 0.909 . . . . 0.0 111.418 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 10.4 t-20 -56.07 -51.98 65.91 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.02 179.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -61.51 -49.02 78.4 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 123.562 0.539 . . . . 0.0 110.252 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.14 75.64 Favored Glycine 0 C--N 1.348 1.236 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.048 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.552 ' O ' ' HG ' ' A' ' 18' ' ' LEU . . . -77.25 -50.7 12.31 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 122.394 0.278 . . . . 0.0 111.023 178.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.7 pt -68.19 -38.71 80.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 45.0 mm -80.88 -35.35 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.03 -42.65 58.87 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.11 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 14' ' ' ALA . 2.3 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 . . . . . 0 N--CA 1.471 0.583 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.502 ' O ' HG13 ' A' ' 8' ' ' VAL . 41.3 p90 -62.44 -45.47 92.94 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.88 -29.82 30.44 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -100.46 -40.22 7.57 Favored 'General case' 0 CA--C 1.535 0.367 0 O-C-N 123.52 0.512 . . . . 0.0 110.575 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.416 ' O ' ' N ' ' A' ' 11' ' ' ASN . 4.4 m-20 -71.13 -15.95 62.53 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 4' ' ' PHE . 0.7 OUTLIER -55.1 -17.99 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.25 -25.11 76.1 Favored Glycine 0 C--N 1.343 0.934 0 C-N-CA 121.7 -0.286 . . . . 0.0 113.231 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.659 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 75.4 m -140.61 -46.52 0.41 Allowed 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.748 0.419 . . . . 0.0 110.687 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . 0.488 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.6 p-10 40.83 -167.94 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 125.117 1.367 . . . . 0.0 114.049 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.429 ' O ' HG22 ' A' ' 16' ' ' ILE . 21.3 tptt -47.43 -47.15 26.9 Favored 'General case' 0 C--N 1.353 0.76 0 C-N-CA 123.451 0.7 . . . . 0.0 111.343 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.24 -44.9 58.04 Favored Glycine 0 C--N 1.35 1.338 0 O-C-N 124.209 0.943 . . . . 0.0 114.302 -179.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.659 ' HB2' ' O ' ' A' ' 10' ' ' SER . . . -89.8 -40.92 12.16 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 117.307 0.554 . . . . 0.0 111.83 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 11' ' ' ASN . 5.0 pt -65.84 -27.03 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.429 HG22 ' O ' ' A' ' 12' ' ' LYS . 2.4 tp -87.25 -38.28 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 178.336 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.38 -36.77 63.05 Favored Glycine 0 C--N 1.346 1.128 0 CA-C-N 115.767 -0.651 . . . . 0.0 113.204 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.6 tp . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 117.985 -1.007 . . . . 0.0 111.615 -179.695 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.24 0.067 . . . . 7.0700000000000003 110.967 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.447 HG11 ' H ' ' A' ' 3' ' ' PHE . 0.7 OUTLIER -113.04 -154.34 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 O-C-N 123.447 0.467 . . . . 4.4299999999999997 109.756 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.447 ' H ' HG11 ' A' ' 2' ' ' VAL . 90.2 m-85 -131.03 -19.56 2.85 Favored 'General case' 0 C--N 1.347 0.468 0 C-N-CA 122.23 0.212 . . . . 6.54 111.554 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.442 ' O ' HG23 ' A' ' 8' ' ' VAL . 7.6 t80 -60.98 -47.99 83.88 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 122.914 0.486 . . . . 6.2699999999999996 111.58 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.24 -27.13 65.48 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.095 0.558 . . . . 3.2599999999999998 112.145 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -92.65 -38.02 12.1 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.945 -0.57 . . . . 4.4900000000000002 110.323 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -70.87 -29.11 65.13 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 115.974 -0.557 . . . . 3.3700000000000001 112.482 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 4' ' ' PHE . 5.3 m -62.0 -23.35 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 112.883 0.697 . . . . 4.5999999999999996 112.883 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.21 -21.75 77.25 Favored Glycine 0 C--N 1.344 0.988 0 O-C-N 123.308 0.38 . . . . 2.0 113.532 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.589 ' O ' ' HB1' ' A' ' 14' ' ' ALA . 72.0 m -123.83 -50.22 1.84 Allowed 'General case' 0 C--O 1.245 0.853 0 CA-C-O 120.868 0.366 . . . . 3.8199999999999998 110.648 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.554 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.8 t30 45.66 -171.17 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.607 1.163 . . . . 4.8700000000000001 113.321 179.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.554 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.2 mptm? -47.33 -46.16 25.21 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.237 0.615 . . . . 5.4699999999999998 111.346 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.31 -45.95 57.76 Favored Glycine 0 C--N 1.35 1.322 0 O-C-N 124.258 0.974 . . . . 2.0499999999999998 114.201 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.589 ' HB1' ' O ' ' A' ' 10' ' ' SER . . . -89.71 -39.09 13.39 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-N 117.321 0.56 . . . . 2.2799999999999998 111.879 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.437 HG12 ' O ' ' A' ' 11' ' ' ASN . 3.3 pt -67.12 -25.83 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 N-CA-C 112.278 0.473 . . . . 3.8199999999999998 112.278 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.9 tp -80.72 -42.09 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.974 -0.38 . . . . 4.2699999999999996 109.974 178.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.52 -42.98 54.35 Favored Glycine 0 C--N 1.346 1.087 0 CA-C-N 115.701 -0.681 . . . . 2.1600000000000001 112.895 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.7 mt . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.152 -0.928 . . . . 5.0099999999999998 110.837 -179.917 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 N--CA 1.488 1.472 0 CA-C-O 120.366 0.126 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.44 HG21 ' CD2' ' A' ' 3' ' ' PHE . 6.7 m -137.9 -151.42 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.517 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.44 ' CD2' HG21 ' A' ' 2' ' ' VAL . 99.4 m-85 63.82 21.13 12.54 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 123.572 0.749 . . . . 0.0 112.052 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.483 ' O ' HG12 ' A' ' 8' ' ' VAL . 31.7 p90 -59.23 -43.37 92.37 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 112.392 0.515 . . . . 0.0 112.392 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.41 -28.34 53.53 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.142 0.577 . . . . 0.0 112.408 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -100.71 -35.75 9.36 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.131 178.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.89 -22.24 62.3 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.579 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 4' ' ' PHE . 1.8 m -56.09 -29.0 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.53 -13.46 71.23 Favored Glycine 0 C--N 1.342 0.913 0 O-C-N 123.244 0.34 . . . . 0.0 113.527 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 29.0 m -128.57 -57.32 1.2 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 122.649 0.38 . . . . 0.0 110.525 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 18.0 -120.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 125.704 1.602 . . . . 0.0 115.085 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.44 ' O ' HG23 ' A' ' 16' ' ' ILE . 8.5 tptm -59.67 -51.05 71.45 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.609 0.764 . . . . 0.0 112.479 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.13 -31.06 48.46 Favored Glycine 0 C--N 1.35 1.345 0 O-C-N 123.828 0.705 . . . . 0.0 113.839 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -93.22 -41.01 10.13 Favored 'General case' 0 C--O 1.24 0.576 0 O-C-N 123.634 0.255 . . . . 0.0 111.047 178.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -66.62 -30.28 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.345 0.403 . . . . 0.0 111.699 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.44 HG23 ' O ' ' A' ' 12' ' ' LYS . 3.4 tp -81.21 -40.8 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.785 0 O-C-N 123.201 0.313 . . . . 0.0 110.165 178.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.36 -41.83 57.97 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.936 178.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 mp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.836 -179.884 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.622 0.248 . . . . 0.0 110.698 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.579 HG11 ' CD2' ' A' ' 3' ' ' PHE . 2.6 t 60.55 -88.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 123.883 0.873 . . . . 0.0 111.129 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.579 ' CD2' HG11 ' A' ' 2' ' ' VAL . 9.7 p90 -161.58 -27.2 0.05 Allowed 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.785 0.434 . . . . 0.0 111.589 179.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -60.3 -47.87 84.19 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 122.963 0.505 . . . . 0.0 112.041 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.18 -27.34 67.05 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -92.59 -42.81 9.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.677 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -70.93 -28.47 64.53 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.62 -23.86 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.38 -18.81 75.56 Favored Glycine 0 C--N 1.343 0.934 0 CA-C-O 119.895 -0.391 . . . . 0.0 113.881 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.4 m -133.53 -45.84 0.82 Allowed 'General case' 0 C--O 1.238 0.461 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.45 ' O ' ' HB ' ' A' ' 15' ' ' ILE . 3.0 t30 -57.97 -48.11 80.96 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.753 0.421 . . . . 0.0 111.752 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.486 ' O ' HG22 ' A' ' 15' ' ' ILE . 12.4 tptp -65.04 -50.48 66.05 Favored 'General case' 0 C--O 1.241 0.612 0 O-C-N 123.3 0.375 . . . . 0.0 110.095 179.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.95 -34.49 83.42 Favored Glycine 0 C--N 1.35 1.36 0 O-C-N 123.946 0.779 . . . . 0.0 112.498 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.36 -39.98 31.32 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 122.256 0.223 . . . . 0.0 110.634 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.486 HG22 ' O ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -68.47 -35.1 69.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.376 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -74.48 -43.89 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-O 120.623 0.249 . . . . 0.0 110.664 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.35 -42.38 56.92 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.009 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.587 -179.795 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.7 tp . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.29 0.091 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 5.7 m -97.92 -159.95 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 123.366 0.416 . . . . 0.0 110.977 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -115.04 22.13 13.65 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 120.893 0.378 . . . . 0.0 111.265 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -61.65 -39.93 93.09 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.113 0.565 . . . . 0.0 111.782 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.06 -31.19 68.65 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.891 0.477 . . . . 0.0 111.822 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -95.03 -34.59 12.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.263 178.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.401 ' O ' HG11 ' A' ' 8' ' ' VAL . 1.6 t70 -70.55 -26.78 63.71 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.834 179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.511 HG21 ' H ' ' A' ' 9' ' ' GLY . 3.9 p 52.58 -149.7 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 C-N-CA 124.289 1.036 . . . . 0.0 110.944 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.511 ' H ' HG21 ' A' ' 8' ' ' VAL . . . -59.54 -55.77 28.7 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 118.361 0.528 . . . . 0.0 113.244 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.4 m -152.78 45.21 0.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 122.419 0.288 . . . . 0.0 111.045 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.661 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.9 p-10 23.93 -100.85 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.661 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.0 OUTLIER -60.67 -53.81 52.86 Favored 'General case' 0 C--N 1.354 0.781 0 C-N-CA 123.226 0.61 . . . . 0.0 110.597 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.09 -27.93 63.21 Favored Glycine 0 C--N 1.349 1.276 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.609 178.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -80.41 -48.61 12.63 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 122.286 0.235 . . . . 0.0 110.674 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.508 HG13 ' O ' ' A' ' 12' ' ' LYS . 2.2 pp -66.74 -41.35 87.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.592 HG21 ' O ' ' A' ' 12' ' ' LYS . 3.3 tp -81.24 -35.1 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 178.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.13 -38.02 63.59 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.759 -0.655 . . . . 0.0 113.217 178.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.9 tt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.535 -179.87 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 12.3 mt . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.85 -51.05 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 O-C-N 123.349 0.405 . . . . 0.0 111.592 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 54.9 30.91 14.77 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 123.67 0.788 . . . . 0.0 112.47 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.491 ' O ' HG11 ' A' ' 8' ' ' VAL . 46.0 p90 -57.03 -45.78 82.87 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.53 -28.58 55.64 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -98.94 -39.37 8.6 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.081 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -70.81 -20.39 62.58 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.577 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 1.4 m -55.53 -31.51 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.59 -16.67 74.14 Favored Glycine 0 CA--C 1.529 0.945 0 O-C-N 123.411 0.444 . . . . 0.0 113.642 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.473 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 63.2 m -119.99 -56.35 2.02 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.484 0.314 . . . . 0.0 110.853 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.577 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER 43.34 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.756 1.222 . . . . 0.0 113.867 179.161 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.0 mmtp -50.81 -39.61 53.51 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 123.147 0.579 . . . . 0.0 111.457 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.65 -46.29 75.21 Favored Glycine 0 C--N 1.351 1.383 0 O-C-N 123.979 0.799 . . . . 0.0 113.259 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.473 ' HB2' ' O ' ' A' ' 10' ' ' SER . . . -87.82 -37.15 16.8 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.691 0.245 . . . . 0.0 110.927 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.7 mt -64.22 -27.75 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 123.205 0.316 . . . . 0.0 111.212 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 3.5 tp -79.93 -42.36 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.33 -43.98 53.22 Favored Glycine 0 C--N 1.345 1.051 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.989 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.6 tp . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.495 -0.764 . . . . 0.0 110.565 -179.907 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 N--CA 1.488 1.454 0 CA-C-O 120.367 0.127 . . . . 0.0 111.15 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.561 ' O ' ' HB2' ' A' ' 6' ' ' GLU . 1.5 t 55.55 -146.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 C-N-CA 123.856 0.862 . . . . 0.0 110.804 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.438 ' H ' HG13 ' A' ' 2' ' ' VAL . 94.5 m-85 59.53 164.98 0.05 Allowed 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 124.655 1.182 . . . . 0.0 112.589 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.462 ' O ' ' HB ' ' A' ' 8' ' ' VAL . 9.7 t80 -70.79 -61.73 1.65 Allowed 'General case' 0 C--N 1.364 1.23 0 CA-C-N 118.764 0.711 . . . . 0.0 111.645 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -56.57 -22.26 32.27 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.561 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 47.1 mt-10 -99.22 -50.07 4.26 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 123.231 0.332 . . . . 0.0 110.949 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -71.02 -17.03 62.64 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 4' ' ' PHE . 11.1 p -58.78 -27.85 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.45 -13.99 71.51 Favored Glycine 0 C--N 1.344 0.973 0 O-C-N 123.329 0.393 . . . . 0.0 113.8 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 42.4 p -128.79 -24.87 2.91 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 122.404 0.282 . . . . 0.0 111.694 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.7 t30 -53.64 -50.99 64.56 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.127 0.571 . . . . 0.0 111.669 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.499 ' O ' HG13 ' A' ' 15' ' ' ILE . 34.1 mtmt -60.17 -53.08 61.94 Favored 'General case' 0 C--O 1.242 0.689 0 O-C-N 123.484 0.49 . . . . 0.0 110.327 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.92 -30.31 69.56 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.406 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.28 -44.66 24.81 Favored 'General case' 0 C--O 1.239 0.55 0 O-C-N 123.71 0.3 . . . . 0.0 111.146 178.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.3 pt -71.24 -34.48 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -71.8 -44.84 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 CA-C-O 120.767 0.318 . . . . 0.0 110.411 178.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.34 -45.17 49.47 Favored Glycine 0 C--N 1.346 1.107 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.842 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.169 0 C-N-CA 123.849 0.86 . . . . 0.0 111.814 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.456 0 N-CA-C 111.277 0.103 . . . . 0.0 111.277 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.574 HG22 ' H ' ' A' ' 3' ' ' PHE . 4.7 p -118.36 -164.24 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.272 0 O-C-N 123.477 0.486 . . . . 0.0 109.974 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.574 ' H ' HG22 ' A' ' 2' ' ' VAL . 88.3 m-85 -136.33 -18.9 1.48 Allowed 'General case' 0 C--N 1.351 0.65 0 CA-C-N 118.179 0.445 . . . . 0.0 111.625 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -64.48 -47.6 78.37 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 122.843 0.457 . . . . 0.0 111.632 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.47 -25.15 64.17 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -97.53 -52.14 3.88 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.377 179.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.52 ' OD2' ' HB3' ' A' ' 3' ' ' PHE . 50.6 m-20 -71.4 -11.14 60.74 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.2 m 28.55 -120.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 178.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.17 -11.87 67.95 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.554 ' O ' ' HB1' ' A' ' 14' ' ' ALA . 70.1 m -81.06 -54.14 5.8 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 122.59 0.356 . . . . 0.0 110.326 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.625 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.3 t30 41.68 -166.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 124.282 1.033 . . . . 0.0 113.649 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.625 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 97.2 mttt -48.87 -43.6 39.06 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.066 0.546 . . . . 0.0 111.245 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -51.79 -40.03 48.37 Favored Glycine 0 C--N 1.355 1.62 0 O-C-N 124.309 1.006 . . . . 0.0 113.772 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.554 ' HB1' ' O ' ' A' ' 10' ' ' SER . . . -93.98 -34.78 12.92 Favored 'General case' 0 C--O 1.241 0.605 0 CA-C-N 116.847 0.323 . . . . 0.0 110.673 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.593 HG12 ' O ' ' A' ' 11' ' ' ASN . 46.2 mm -63.18 -33.39 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 CA-C-O 119.034 -0.507 . . . . 0.0 112.271 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.566 HG22 ' O ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -84.21 -35.11 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.458 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.46 ' H ' HD12 ' A' ' 16' ' ' ILE . . . -71.3 -43.03 56.03 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.925 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.935 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.422 ' H2 ' HD23 ' A' ' 1' ' ' LEU . 4.0 mm? . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.717 0.294 . . . . 0.0 110.58 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 t -131.16 -65.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.279 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.489 ' HB2' ' OD2' ' A' ' 7' ' ' ASP . 40.0 p90 -144.81 -19.35 0.51 Allowed 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -58.01 -45.0 87.59 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 122.931 0.492 . . . . 0.0 112.221 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -58.1 -36.19 72.52 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.09 -37.95 13.89 Favored 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.432 0.457 . . . . 0.0 111.115 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.489 ' OD2' ' HB2' ' A' ' 3' ' ' PHE . 6.5 m-20 -70.72 -29.68 66.01 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.0 p -62.86 -28.54 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.57 -12.36 69.96 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.412 0.445 . . . . 0.0 113.876 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.7 t -130.64 -50.6 1.06 Allowed 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.778 0.289 . . . . 0.0 111.375 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -57.58 -51.2 70.44 Favored 'General case' 0 N--CA 1.475 0.813 0 O-C-N 123.276 0.36 . . . . 0.0 111.474 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.485 ' O ' HG13 ' A' ' 15' ' ' ILE . 12.1 tptm -60.19 -52.16 66.48 Favored 'General case' 0 C--O 1.242 0.673 0 O-C-N 123.498 0.499 . . . . 0.0 109.915 179.089 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.01 -31.69 73.34 Favored Glycine 0 C--N 1.35 1.327 0 O-C-N 124.013 0.821 . . . . 0.0 112.441 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.36 -44.87 27.89 Favored 'General case' 0 C--O 1.239 0.534 0 C-N-CA 122.324 0.25 . . . . 0.0 111.08 178.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.485 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.4 pt -70.92 -34.08 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -72.45 -44.67 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.403 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.65 -44.15 49.96 Favored Glycine 0 C--N 1.345 1.037 0 CA-C-N 115.487 -0.779 . . . . 0.0 112.86 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.84 -179.913 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.558 ' O ' ' HB2' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -130.03 -143.1 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.949 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.43 ' CE2' ' HD2' ' A' ' 4' ' ' PHE . 3.1 t80 81.29 -176.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 125.18 1.392 . . . . 0.0 111.556 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.43 ' HD2' ' CE2' ' A' ' 3' ' ' PHE . 87.9 m-85 -60.52 -57.9 10.78 Favored 'General case' 0 C--N 1.36 1.059 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.091 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.83 -25.68 30.05 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.558 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 43.3 mt-10 -101.69 -41.24 6.63 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 123.196 0.31 . . . . 0.0 111.54 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -70.26 -31.97 69.59 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.62 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 59.0 t -81.73 -27.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 123.16 0.287 . . . . 0.0 110.759 -179.153 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.43 -11.37 68.07 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 123.196 0.31 . . . . 0.0 113.019 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.641 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 67.3 m -128.33 -46.61 1.33 Allowed 'General case' 0 C--O 1.244 0.8 0 C-N-CA 122.843 0.457 . . . . 0.0 110.736 179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.62 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER 45.13 -169.12 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.472 1.109 . . . . 0.0 113.662 179.288 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.56 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 31.4 tttp -48.92 -45.98 42.31 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.521 0.728 . . . . 0.0 111.377 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.7 -47.1 65.51 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 114.979 -1.01 . . . . 0.0 114.271 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.641 ' HB2' ' O ' ' A' ' 10' ' ' SER . . . -88.53 -41.46 12.7 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 117.248 0.524 . . . . 0.0 111.735 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.3 tt -63.55 -30.2 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.56 ' HB ' ' O ' ' A' ' 12' ' ' LYS . 1.2 mp -92.3 -36.31 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -70.85 -29.1 69.67 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-N 115.896 -0.593 . . . . 0.0 113.412 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.083 -0.96 . . . . 0.0 110.656 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 111.421 0.156 . . . . 0.0 111.421 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.519 HG13 ' CD2' ' A' ' 3' ' ' PHE . 7.6 p -95.08 -49.8 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 O-C-N 123.42 0.45 . . . . 0.0 110.785 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.519 ' CD2' HG13 ' A' ' 2' ' ' VAL . 18.9 p90 -135.47 -17.79 1.74 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 123.231 0.332 . . . . 0.0 111.651 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -65.28 -44.54 87.69 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.778 0.431 . . . . 0.0 111.58 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -65.61 -23.93 66.94 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.939 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -92.11 -44.57 8.75 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.335 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.477 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 3.1 t70 -70.92 -29.31 65.32 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.638 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 m 42.53 -153.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 124.646 1.178 . . . . 0.0 112.59 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 66.87 0.87 Allowed Glycine 0 C--N 1.352 1.453 0 C-N-CA 121.73 -0.272 . . . . 0.0 112.587 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 20.3 t 63.24 66.89 0.69 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.973 0.909 . . . . 0.0 111.418 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.477 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 10.4 t-20 -56.07 -51.98 65.91 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.02 179.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -61.51 -49.02 78.4 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 123.562 0.539 . . . . 0.0 110.252 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.14 75.64 Favored Glycine 0 C--N 1.348 1.236 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.048 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.552 ' O ' ' HG ' ' A' ' 18' ' ' LEU . . . -77.25 -50.7 12.31 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 122.394 0.278 . . . . 0.0 111.023 178.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.7 pt -68.19 -38.71 80.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 45.0 mm -80.88 -35.35 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.03 -42.65 58.87 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.11 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 14' ' ' ALA . 2.3 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LEU . . . . . 0.485 HD23 ' H1 ' ' A' ' 1' ' ' LEU . 2.7 mm? . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.617 0.246 . . . . 0.0 110.507 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.411 HG23 ' H ' ' A' ' 3' ' ' PHE . 2.5 m -144.97 -63.47 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.817 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.411 ' H ' HG23 ' A' ' 2' ' ' VAL . 90.1 m-85 -145.89 -54.91 0.28 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 123.029 0.205 . . . . 0.0 111.445 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.502 ' O ' HG13 ' A' ' 8' ' ' VAL . 41.3 p90 -62.44 -45.47 92.94 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.88 -29.82 30.44 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -100.46 -40.22 7.57 Favored 'General case' 0 CA--C 1.535 0.367 0 O-C-N 123.52 0.512 . . . . 0.0 110.575 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.416 ' O ' ' N ' ' A' ' 11' ' ' ASN . 4.4 m-20 -71.13 -15.95 62.53 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 4' ' ' PHE . 0.7 OUTLIER -55.1 -17.99 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.25 -25.11 76.1 Favored Glycine 0 C--N 1.343 0.934 0 C-N-CA 121.7 -0.286 . . . . 0.0 113.231 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.659 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 75.4 m -140.61 -46.52 0.41 Allowed 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.748 0.419 . . . . 0.0 110.687 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.488 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.6 p-10 40.83 -167.94 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 125.117 1.367 . . . . 0.0 114.049 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.429 ' O ' HG22 ' A' ' 16' ' ' ILE . 21.3 tptt -47.43 -47.15 26.9 Favored 'General case' 0 C--N 1.353 0.76 0 C-N-CA 123.451 0.7 . . . . 0.0 111.343 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.24 -44.9 58.04 Favored Glycine 0 C--N 1.35 1.338 0 O-C-N 124.209 0.943 . . . . 0.0 114.302 -179.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.659 ' HB2' ' O ' ' A' ' 10' ' ' SER . . . -89.8 -40.92 12.16 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 117.307 0.554 . . . . 0.0 111.83 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 11' ' ' ASN . 5.0 pt -65.84 -27.03 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.429 HG22 ' O ' ' A' ' 12' ' ' LYS . 2.4 tp -87.25 -38.28 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 178.336 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.38 -36.77 63.05 Favored Glycine 0 C--N 1.346 1.128 0 CA-C-N 115.767 -0.651 . . . . 0.0 113.204 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.6 tp . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 117.985 -1.007 . . . . 0.0 111.615 -179.695 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 N--CA 1.467 0.425 0 N-CA-C 111.554 0.205 . . . . 5.71 111.554 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.459 ' O ' HG22 ' A' ' 8' ' ' VAL . 7.6 t80 -60.98 -47.99 83.88 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 122.914 0.486 . . . . 5.4000000000000004 111.58 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.24 -27.13 65.48 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.095 0.558 . . . . 3.0299999999999998 112.145 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -92.65 -38.02 12.1 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.945 -0.57 . . . . 4.4900000000000002 110.323 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -70.87 -29.11 65.13 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 115.974 -0.557 . . . . 3.3700000000000001 112.482 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 4' ' ' PHE . 5.3 m -62.0 -23.35 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 112.883 0.697 . . . . 3.9100000000000001 112.883 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.21 -21.75 77.25 Favored Glycine 0 C--N 1.344 0.988 0 O-C-N 123.308 0.38 . . . . 1.8899999999999999 113.532 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.0 m -123.83 -50.22 1.84 Allowed 'General case' 0 C--O 1.245 0.853 0 CA-C-O 120.868 0.366 . . . . 3.4100000000000001 110.648 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.461 ' O ' HG12 ' A' ' 15' ' ' ILE . 1.5 t-20 45.66 -171.17 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.607 1.163 . . . . 4.1699999999999999 113.321 179.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -47.33 -46.16 25.21 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.237 0.615 . . . . 5.0099999999999998 111.346 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.31 -45.95 57.76 Favored Glycine 0 C--N 1.35 1.322 0 O-C-N 124.258 0.974 . . . . 1.6499999999999999 114.201 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -89.71 -39.09 13.39 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-N 117.321 0.56 . . . . 1.74 111.879 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 11' ' ' ASN . 3.3 pt -67.12 -25.83 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 N-CA-C 112.278 0.473 . . . . 3.3599999999999999 112.278 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.9 tp -80.72 -42.09 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.974 -0.38 . . . . 3.7599999999999998 109.974 178.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.52 -42.98 54.35 Favored Glycine 0 C--N 1.346 1.087 0 CA-C-N 115.701 -0.681 . . . . 2.1600000000000001 112.895 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.7 mt . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.152 -0.928 . . . . 4.4199999999999999 110.837 -179.917 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.491 ' O ' HG13 ' A' ' 8' ' ' VAL . 31.7 p90 -59.23 -43.37 92.37 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 112.392 0.515 . . . . 0.0 112.392 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.41 -28.34 53.53 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.142 0.577 . . . . 0.0 112.408 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -100.71 -35.75 9.36 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.131 178.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.89 -22.24 62.3 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.579 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.491 HG13 ' O ' ' A' ' 4' ' ' PHE . 1.8 m -56.09 -29.0 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.53 -13.46 71.23 Favored Glycine 0 C--N 1.342 0.913 0 O-C-N 123.244 0.34 . . . . 0.0 113.527 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 29.0 m -128.57 -57.32 1.2 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 122.649 0.38 . . . . 0.0 110.525 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 18.0 -120.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 125.704 1.602 . . . . 0.0 115.085 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.64 ' HA ' HG22 ' A' ' 15' ' ' ILE . 8.5 tptm -59.67 -51.05 71.45 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.609 0.764 . . . . 0.0 112.479 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.13 -31.06 48.46 Favored Glycine 0 C--N 1.35 1.345 0 O-C-N 123.828 0.705 . . . . 0.0 113.839 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -93.22 -41.01 10.13 Favored 'General case' 0 C--O 1.24 0.576 0 O-C-N 123.634 0.255 . . . . 0.0 111.047 178.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.64 HG22 ' HA ' ' A' ' 12' ' ' LYS . 1.0 OUTLIER -66.62 -30.28 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.345 0.403 . . . . 0.0 111.699 -179.79 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.446 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.4 tp -81.21 -40.8 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.785 0 O-C-N 123.201 0.313 . . . . 0.0 110.165 178.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.36 -41.83 57.97 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.936 178.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 mp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.836 -179.884 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.7 p90 . . . . . 0 N--CA 1.478 0.953 0 N-CA-C 111.589 0.218 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -60.3 -47.87 84.19 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 122.963 0.505 . . . . 0.0 112.041 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.18 -27.34 67.05 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -92.59 -42.81 9.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.677 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -70.93 -28.47 64.53 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.62 -23.86 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.38 -18.81 75.56 Favored Glycine 0 C--N 1.343 0.934 0 CA-C-O 119.895 -0.391 . . . . 0.0 113.881 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.4 m -133.53 -45.84 0.82 Allowed 'General case' 0 C--O 1.238 0.461 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.461 ' O ' ' HB ' ' A' ' 15' ' ' ILE . 3.0 t30 -57.97 -48.11 80.96 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.753 0.421 . . . . 0.0 111.752 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.464 ' HA ' HG22 ' A' ' 15' ' ' ILE . 12.4 tptp -65.04 -50.48 66.05 Favored 'General case' 0 C--O 1.241 0.612 0 O-C-N 123.3 0.375 . . . . 0.0 110.095 179.254 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.95 -34.49 83.42 Favored Glycine 0 C--N 1.35 1.36 0 O-C-N 123.946 0.779 . . . . 0.0 112.498 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.36 -39.98 31.32 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 122.256 0.223 . . . . 0.0 110.634 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.464 HG22 ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -68.47 -35.1 69.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.376 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -74.48 -43.89 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-O 120.623 0.249 . . . . 0.0 110.664 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.35 -42.38 56.92 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.009 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.587 -179.795 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 p90 . . . . . 0 CA--C 1.544 0.717 0 CA-C-O 120.893 0.378 . . . . 0.0 111.265 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -61.65 -39.93 93.09 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.113 0.565 . . . . 0.0 111.782 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.06 -31.19 68.65 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.891 0.477 . . . . 0.0 111.822 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -95.03 -34.59 12.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.263 178.621 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -26.78 63.71 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.834 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 9' ' ' GLY . 3.9 p 52.58 -149.7 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 C-N-CA 124.289 1.036 . . . . 0.0 110.944 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.541 ' H ' HG22 ' A' ' 8' ' ' VAL . . . -59.54 -55.77 28.7 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 118.361 0.528 . . . . 0.0 113.244 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.491 ' H ' ' HB2' ' A' ' 14' ' ' ALA . 50.4 m -152.78 45.21 0.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 122.419 0.288 . . . . 0.0 111.045 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.3 p30 23.93 -100.85 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.592 ' O ' HG22 ' A' ' 16' ' ' ILE . 1.0 OUTLIER -60.67 -53.81 52.86 Favored 'General case' 0 C--N 1.354 0.781 0 C-N-CA 123.226 0.61 . . . . 0.0 110.597 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.09 -27.93 63.21 Favored Glycine 0 C--N 1.349 1.276 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.609 178.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB2' ' H ' ' A' ' 10' ' ' SER . . . -80.41 -48.61 12.63 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 122.286 0.235 . . . . 0.0 110.674 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 12' ' ' LYS . 2.2 pp -66.74 -41.35 87.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.3 tp -81.24 -35.1 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 178.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.13 -38.02 63.59 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.759 -0.655 . . . . 0.0 113.217 178.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.9 tt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.535 -179.87 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 . . . . . 0 N--CA 1.486 1.339 0 N-CA-C 112.47 0.545 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.5 ' O ' HG13 ' A' ' 8' ' ' VAL . 46.0 p90 -57.03 -45.78 82.87 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.53 -28.58 55.64 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -98.94 -39.37 8.6 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.081 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -70.81 -20.39 62.58 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.601 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 1.4 m -55.53 -31.51 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.59 -16.67 74.14 Favored Glycine 0 CA--C 1.529 0.945 0 O-C-N 123.411 0.444 . . . . 0.0 113.642 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 63.2 m -119.99 -56.35 2.02 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.484 0.314 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.601 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER 43.34 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.756 1.222 . . . . 0.0 113.867 179.161 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.0 mmtp -50.81 -39.61 53.51 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 123.147 0.579 . . . . 0.0 111.457 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.65 -46.29 75.21 Favored Glycine 0 C--N 1.351 1.383 0 O-C-N 123.979 0.799 . . . . 0.0 113.259 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.82 -37.15 16.8 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.691 0.245 . . . . 0.0 110.927 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.7 mt -64.22 -27.75 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 123.205 0.316 . . . . 0.0 111.212 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 3.5 tp -79.93 -42.36 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.33 -43.98 53.22 Favored Glycine 0 C--N 1.345 1.051 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.989 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.6 tp . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.495 -0.764 . . . . 0.0 110.565 -179.907 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 . . . . . 0 N--CA 1.488 1.457 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.48 ' O ' ' HB ' ' A' ' 8' ' ' VAL . 9.7 t80 -70.79 -61.73 1.65 Allowed 'General case' 0 C--N 1.364 1.23 0 CA-C-N 118.764 0.711 . . . . 0.0 111.645 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -56.57 -22.26 32.27 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -99.22 -50.07 4.26 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 123.231 0.332 . . . . 0.0 110.949 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.405 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 2.1 t70 -71.02 -17.03 62.64 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' A' ' 4' ' ' PHE . 11.1 p -58.78 -27.85 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.45 -13.99 71.51 Favored Glycine 0 C--N 1.344 0.973 0 O-C-N 123.329 0.393 . . . . 0.0 113.8 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 42.4 p -128.79 -24.87 2.91 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 122.404 0.282 . . . . 0.0 111.694 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.405 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 41.7 t30 -53.64 -50.99 64.56 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.127 0.571 . . . . 0.0 111.669 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.514 ' O ' HG13 ' A' ' 15' ' ' ILE . 34.1 mtmt -60.17 -53.08 61.94 Favored 'General case' 0 C--O 1.242 0.689 0 O-C-N 123.484 0.49 . . . . 0.0 110.327 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.92 -30.31 69.56 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.406 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.28 -44.66 24.81 Favored 'General case' 0 C--O 1.239 0.55 0 O-C-N 123.71 0.3 . . . . 0.0 111.146 178.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.3 pt -71.24 -34.48 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -71.8 -44.84 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 CA-C-O 120.767 0.318 . . . . 0.0 110.411 178.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.34 -45.17 49.47 Favored Glycine 0 C--N 1.346 1.107 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.842 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.169 0 C-N-CA 123.849 0.86 . . . . 0.0 111.814 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.531 ' HB3' ' OD2' ' A' ' 7' ' ' ASP . 88.3 m-85 . . . . . 0 N--CA 1.469 0.499 0 N-CA-C 111.625 0.232 . . . . 0.0 111.625 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -64.48 -47.6 78.37 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 122.843 0.457 . . . . 0.0 111.632 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.47 -25.15 64.17 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -97.53 -52.14 3.88 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.377 179.33 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 3' ' ' PHE . 50.6 m-20 -71.4 -11.14 60.74 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.2 m 28.55 -120.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 178.155 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.17 -11.87 67.95 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.447 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 70.1 m -81.06 -54.14 5.8 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 122.59 0.356 . . . . 0.0 110.326 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.61 ' O ' HG12 ' A' ' 15' ' ' ILE . 1.4 t-20 41.68 -166.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 124.282 1.033 . . . . 0.0 113.649 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.575 ' O ' HG23 ' A' ' 16' ' ' ILE . 97.2 mttt -48.87 -43.6 39.06 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.066 0.546 . . . . 0.0 111.245 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -51.79 -40.03 48.37 Favored Glycine 0 C--N 1.355 1.62 0 O-C-N 124.309 1.006 . . . . 0.0 113.772 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.447 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -93.98 -34.78 12.92 Favored 'General case' 0 C--O 1.241 0.605 0 CA-C-N 116.847 0.323 . . . . 0.0 110.673 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.61 HG12 ' O ' ' A' ' 11' ' ' ASN . 46.2 mm -63.18 -33.39 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 CA-C-O 119.034 -0.507 . . . . 0.0 112.271 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -84.21 -35.11 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.458 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.474 ' H ' HD13 ' A' ' 16' ' ' ILE . . . -71.3 -43.03 56.03 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.925 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.935 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB2' ' OD2' ' A' ' 7' ' ' ASP . 40.0 p90 . . . . . 0 N--CA 1.473 0.689 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -58.01 -45.0 87.59 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 122.931 0.492 . . . . 0.0 112.221 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -58.1 -36.19 72.52 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.09 -37.95 13.89 Favored 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.432 0.457 . . . . 0.0 111.115 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.492 ' OD2' ' HB2' ' A' ' 3' ' ' PHE . 6.5 m-20 -70.72 -29.68 66.01 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.0 p -62.86 -28.54 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.57 -12.36 69.96 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.412 0.445 . . . . 0.0 113.876 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.7 t -130.64 -50.6 1.06 Allowed 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.778 0.289 . . . . 0.0 111.375 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -57.58 -51.2 70.44 Favored 'General case' 0 N--CA 1.475 0.813 0 O-C-N 123.276 0.36 . . . . 0.0 111.474 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 15' ' ' ILE . 12.1 tptm -60.19 -52.16 66.48 Favored 'General case' 0 C--O 1.242 0.673 0 O-C-N 123.498 0.499 . . . . 0.0 109.915 179.089 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.01 -31.69 73.34 Favored Glycine 0 C--N 1.35 1.327 0 O-C-N 124.013 0.821 . . . . 0.0 112.441 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.36 -44.87 27.89 Favored 'General case' 0 C--O 1.239 0.534 0 C-N-CA 122.324 0.25 . . . . 0.0 111.08 178.476 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.4 pt -70.92 -34.08 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -72.45 -44.67 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.403 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.65 -44.15 49.96 Favored Glycine 0 C--N 1.345 1.037 0 CA-C-N 115.487 -0.779 . . . . 0.0 112.86 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.84 -179.913 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . 0.43 ' CE2' ' HD2' ' A' ' 4' ' ' PHE . 3.1 t80 . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 119.603 -0.237 . . . . 0.0 111.556 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.43 ' HD2' ' CE2' ' A' ' 3' ' ' PHE . 87.9 m-85 -60.52 -57.9 10.78 Favored 'General case' 0 C--N 1.36 1.059 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.091 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.83 -25.68 30.05 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -101.69 -41.24 6.63 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 123.196 0.31 . . . . 0.0 111.54 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -70.26 -31.97 69.59 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.628 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 59.0 t -81.73 -27.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 123.16 0.287 . . . . 0.0 110.759 -179.153 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.43 -11.37 68.07 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 123.196 0.31 . . . . 0.0 113.019 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.441 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 67.3 m -128.33 -46.61 1.33 Allowed 'General case' 0 C--O 1.244 0.8 0 C-N-CA 122.843 0.457 . . . . 0.0 110.736 179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.628 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER 45.13 -169.12 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.472 1.109 . . . . 0.0 113.662 179.288 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.585 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 31.4 tttp -48.92 -45.98 42.31 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.521 0.728 . . . . 0.0 111.377 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.7 -47.1 65.51 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 114.979 -1.01 . . . . 0.0 114.271 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.441 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -88.53 -41.46 12.7 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 117.248 0.524 . . . . 0.0 111.735 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.708 HG23 HD12 ' A' ' 16' ' ' ILE . 1.3 tt -63.55 -30.2 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.708 HD12 HG23 ' A' ' 15' ' ' ILE . 1.2 mp -92.3 -36.31 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.076 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -70.85 -29.1 69.67 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-N 115.896 -0.593 . . . . 0.0 113.412 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.083 -0.96 . . . . 0.0 110.656 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 18.9 p90 . . . . . 0 N--CA 1.471 0.607 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -65.28 -44.54 87.69 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.778 0.431 . . . . 0.0 111.58 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -65.61 -23.93 66.94 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.939 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -92.11 -44.57 8.75 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.335 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 3.1 t70 -70.92 -29.31 65.32 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.638 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 m 42.53 -153.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 124.646 1.178 . . . . 0.0 112.59 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 66.87 0.87 Allowed Glycine 0 C--N 1.352 1.453 0 C-N-CA 121.73 -0.272 . . . . 0.0 112.587 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 20.3 t 63.24 66.89 0.69 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.973 0.909 . . . . 0.0 111.418 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.493 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 10.4 t-20 -56.07 -51.98 65.91 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.02 179.6 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -61.51 -49.02 78.4 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 123.562 0.539 . . . . 0.0 110.252 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.14 75.64 Favored Glycine 0 C--N 1.348 1.236 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.048 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.562 ' O ' ' HG ' ' A' ' 18' ' ' LEU . . . -77.25 -50.7 12.31 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 122.394 0.278 . . . . 0.0 111.023 178.176 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.7 pt -68.19 -38.71 80.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 45.0 mm -80.88 -35.35 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.03 -42.65 58.87 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.11 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 14' ' ' ALA . 2.3 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 . . . . . 0 N--CA 1.471 0.583 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.52 ' O ' HG13 ' A' ' 8' ' ' VAL . 41.3 p90 -62.44 -45.47 92.94 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.88 -29.82 30.44 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -100.46 -40.22 7.57 Favored 'General case' 0 CA--C 1.535 0.367 0 O-C-N 123.52 0.512 . . . . 0.0 110.575 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.416 ' O ' ' N ' ' A' ' 11' ' ' ASN . 4.4 m-20 -71.13 -15.95 62.53 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.52 HG13 ' O ' ' A' ' 4' ' ' PHE . 0.7 OUTLIER -55.1 -17.99 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.25 -25.11 76.1 Favored Glycine 0 C--N 1.343 0.934 0 C-N-CA 121.7 -0.286 . . . . 0.0 113.231 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.462 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 75.4 m -140.61 -46.52 0.41 Allowed 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.748 0.419 . . . . 0.0 110.687 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.514 ' O ' HG12 ' A' ' 15' ' ' ILE . 8.3 p30 40.83 -167.94 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 125.117 1.367 . . . . 0.0 114.049 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.432 ' O ' HG22 ' A' ' 16' ' ' ILE . 21.3 tptt -47.43 -47.15 26.9 Favored 'General case' 0 C--N 1.353 0.76 0 C-N-CA 123.451 0.7 . . . . 0.0 111.343 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.24 -44.9 58.04 Favored Glycine 0 C--N 1.35 1.338 0 O-C-N 124.209 0.943 . . . . 0.0 114.302 -179.372 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.462 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -89.8 -40.92 12.16 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 117.307 0.554 . . . . 0.0 111.83 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 11' ' ' ASN . 5.0 pt -65.84 -27.03 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.432 HG22 ' O ' ' A' ' 12' ' ' LYS . 2.4 tp -87.25 -38.28 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 178.336 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.38 -36.77 63.05 Favored Glycine 0 C--N 1.346 1.128 0 CA-C-N 115.767 -0.651 . . . . 0.0 113.204 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.6 tp . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 117.985 -1.007 . . . . 0.0 111.615 -179.695 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.24 0.067 . . . . 6.7199999999999998 110.967 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.463 HG12 ' H ' ' A' ' 3' ' ' PHE . 0.7 OUTLIER -113.04 -154.34 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 O-C-N 123.447 0.467 . . . . 3.8399999999999999 109.756 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.463 ' H ' HG12 ' A' ' 2' ' ' VAL . 90.2 m-85 -131.03 -19.56 2.85 Favored 'General case' 0 C--N 1.347 0.468 0 C-N-CA 122.23 0.212 . . . . 5.71 111.554 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.459 ' O ' HG22 ' A' ' 8' ' ' VAL . 7.6 t80 -60.98 -47.99 83.88 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 122.914 0.486 . . . . 5.4000000000000004 111.58 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.24 -27.13 65.48 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.095 0.558 . . . . 3.0299999999999998 112.145 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -92.65 -38.02 12.1 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.945 -0.57 . . . . 4.4900000000000002 110.323 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -70.87 -29.11 65.13 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 115.974 -0.557 . . . . 3.3700000000000001 112.482 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 4' ' ' PHE . 5.3 m -62.0 -23.35 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 112.883 0.697 . . . . 3.9100000000000001 112.883 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.21 -21.75 77.25 Favored Glycine 0 C--N 1.344 0.988 0 O-C-N 123.308 0.38 . . . . 1.8899999999999999 113.532 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.0 m -123.83 -50.22 1.84 Allowed 'General case' 0 C--O 1.245 0.853 0 CA-C-O 120.868 0.366 . . . . 3.4100000000000001 110.648 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.461 ' O ' HG12 ' A' ' 15' ' ' ILE . 1.5 t-20 45.66 -171.17 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.607 1.163 . . . . 4.1699999999999999 113.321 179.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -47.33 -46.16 25.21 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.237 0.615 . . . . 5.0099999999999998 111.346 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.31 -45.95 57.76 Favored Glycine 0 C--N 1.35 1.322 0 O-C-N 124.258 0.974 . . . . 1.6499999999999999 114.201 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -89.71 -39.09 13.39 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-N 117.321 0.56 . . . . 1.74 111.879 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 11' ' ' ASN . 3.3 pt -67.12 -25.83 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 N-CA-C 112.278 0.473 . . . . 3.3599999999999999 112.278 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.9 tp -80.72 -42.09 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.974 -0.38 . . . . 3.7599999999999998 109.974 178.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.52 -42.98 54.35 Favored Glycine 0 C--N 1.346 1.087 0 CA-C-N 115.701 -0.681 . . . . 2.1600000000000001 112.895 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.7 mt . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.152 -0.928 . . . . 4.4199999999999999 110.837 -179.917 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 N--CA 1.488 1.472 0 CA-C-O 120.366 0.126 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.457 HG23 ' CD2' ' A' ' 3' ' ' PHE . 6.7 m -137.9 -151.42 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.517 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.457 ' CD2' HG23 ' A' ' 2' ' ' VAL . 99.4 m-85 63.82 21.13 12.54 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 123.572 0.749 . . . . 0.0 112.052 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.491 ' O ' HG13 ' A' ' 8' ' ' VAL . 31.7 p90 -59.23 -43.37 92.37 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 112.392 0.515 . . . . 0.0 112.392 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.41 -28.34 53.53 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.142 0.577 . . . . 0.0 112.408 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -100.71 -35.75 9.36 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.131 178.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.89 -22.24 62.3 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.579 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.491 HG13 ' O ' ' A' ' 4' ' ' PHE . 1.8 m -56.09 -29.0 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.53 -13.46 71.23 Favored Glycine 0 C--N 1.342 0.913 0 O-C-N 123.244 0.34 . . . . 0.0 113.527 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 29.0 m -128.57 -57.32 1.2 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 122.649 0.38 . . . . 0.0 110.525 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 18.0 -120.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 125.704 1.602 . . . . 0.0 115.085 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.64 ' HA ' HG22 ' A' ' 15' ' ' ILE . 8.5 tptm -59.67 -51.05 71.45 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.609 0.764 . . . . 0.0 112.479 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.13 -31.06 48.46 Favored Glycine 0 C--N 1.35 1.345 0 O-C-N 123.828 0.705 . . . . 0.0 113.839 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -93.22 -41.01 10.13 Favored 'General case' 0 C--O 1.24 0.576 0 O-C-N 123.634 0.255 . . . . 0.0 111.047 178.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.64 HG22 ' HA ' ' A' ' 12' ' ' LYS . 1.0 OUTLIER -66.62 -30.28 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.345 0.403 . . . . 0.0 111.699 -179.79 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.446 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.4 tp -81.21 -40.8 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.785 0 O-C-N 123.201 0.313 . . . . 0.0 110.165 178.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.36 -41.83 57.97 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.936 178.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 mp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.836 -179.884 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.622 0.248 . . . . 0.0 110.698 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.583 HG12 ' CD2' ' A' ' 3' ' ' PHE . 2.6 t 60.55 -88.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 123.883 0.873 . . . . 0.0 111.129 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.583 ' CD2' HG12 ' A' ' 2' ' ' VAL . 9.7 p90 -161.58 -27.2 0.05 Allowed 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.785 0.434 . . . . 0.0 111.589 179.359 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -60.3 -47.87 84.19 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 122.963 0.505 . . . . 0.0 112.041 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.18 -27.34 67.05 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -92.59 -42.81 9.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.677 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -70.93 -28.47 64.53 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.62 -23.86 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.38 -18.81 75.56 Favored Glycine 0 C--N 1.343 0.934 0 CA-C-O 119.895 -0.391 . . . . 0.0 113.881 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.4 m -133.53 -45.84 0.82 Allowed 'General case' 0 C--O 1.238 0.461 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.461 ' O ' ' HB ' ' A' ' 15' ' ' ILE . 3.0 t30 -57.97 -48.11 80.96 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.753 0.421 . . . . 0.0 111.752 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.464 ' HA ' HG22 ' A' ' 15' ' ' ILE . 12.4 tptp -65.04 -50.48 66.05 Favored 'General case' 0 C--O 1.241 0.612 0 O-C-N 123.3 0.375 . . . . 0.0 110.095 179.254 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.95 -34.49 83.42 Favored Glycine 0 C--N 1.35 1.36 0 O-C-N 123.946 0.779 . . . . 0.0 112.498 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.36 -39.98 31.32 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 122.256 0.223 . . . . 0.0 110.634 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.464 HG22 ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -68.47 -35.1 69.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.376 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -74.48 -43.89 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-O 120.623 0.249 . . . . 0.0 110.664 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.35 -42.38 56.92 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.009 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.587 -179.795 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.7 tp . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.29 0.091 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 5.7 m -97.92 -159.95 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 123.366 0.416 . . . . 0.0 110.977 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -115.04 22.13 13.65 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 120.893 0.378 . . . . 0.0 111.265 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -61.65 -39.93 93.09 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.113 0.565 . . . . 0.0 111.782 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.06 -31.19 68.65 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.891 0.477 . . . . 0.0 111.822 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -95.03 -34.59 12.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.263 178.621 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -26.78 63.71 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.834 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 9' ' ' GLY . 3.9 p 52.58 -149.7 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 C-N-CA 124.289 1.036 . . . . 0.0 110.944 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.541 ' H ' HG22 ' A' ' 8' ' ' VAL . . . -59.54 -55.77 28.7 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 118.361 0.528 . . . . 0.0 113.244 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.491 ' H ' ' HB2' ' A' ' 14' ' ' ALA . 50.4 m -152.78 45.21 0.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 122.419 0.288 . . . . 0.0 111.045 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.3 p30 23.93 -100.85 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.592 ' O ' HG22 ' A' ' 16' ' ' ILE . 1.0 OUTLIER -60.67 -53.81 52.86 Favored 'General case' 0 C--N 1.354 0.781 0 C-N-CA 123.226 0.61 . . . . 0.0 110.597 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.09 -27.93 63.21 Favored Glycine 0 C--N 1.349 1.276 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.609 178.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB2' ' H ' ' A' ' 10' ' ' SER . . . -80.41 -48.61 12.63 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 122.286 0.235 . . . . 0.0 110.674 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 12' ' ' LYS . 2.2 pp -66.74 -41.35 87.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.3 tp -81.24 -35.1 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 178.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.13 -38.02 63.59 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.759 -0.655 . . . . 0.0 113.217 178.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.9 tt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.535 -179.87 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 12.3 mt . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.85 -51.05 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 O-C-N 123.349 0.405 . . . . 0.0 111.592 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 54.9 30.91 14.77 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 123.67 0.788 . . . . 0.0 112.47 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.5 ' O ' HG13 ' A' ' 8' ' ' VAL . 46.0 p90 -57.03 -45.78 82.87 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.53 -28.58 55.64 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -98.94 -39.37 8.6 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.081 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -70.81 -20.39 62.58 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.601 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 1.4 m -55.53 -31.51 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.59 -16.67 74.14 Favored Glycine 0 CA--C 1.529 0.945 0 O-C-N 123.411 0.444 . . . . 0.0 113.642 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 63.2 m -119.99 -56.35 2.02 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.484 0.314 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.601 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER 43.34 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.756 1.222 . . . . 0.0 113.867 179.161 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.0 mmtp -50.81 -39.61 53.51 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 123.147 0.579 . . . . 0.0 111.457 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.65 -46.29 75.21 Favored Glycine 0 C--N 1.351 1.383 0 O-C-N 123.979 0.799 . . . . 0.0 113.259 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.82 -37.15 16.8 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.691 0.245 . . . . 0.0 110.927 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.7 mt -64.22 -27.75 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 123.205 0.316 . . . . 0.0 111.212 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 3.5 tp -79.93 -42.36 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.33 -43.98 53.22 Favored Glycine 0 C--N 1.345 1.051 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.989 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.6 tp . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.495 -0.764 . . . . 0.0 110.565 -179.907 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 N--CA 1.488 1.454 0 CA-C-O 120.367 0.127 . . . . 0.0 111.15 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.58 ' O ' ' HB2' ' A' ' 6' ' ' GLU . 1.5 t 55.55 -146.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 C-N-CA 123.856 0.862 . . . . 0.0 110.804 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.473 ' H ' HG12 ' A' ' 2' ' ' VAL . 94.5 m-85 59.53 164.98 0.05 Allowed 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 124.655 1.182 . . . . 0.0 112.589 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.48 ' O ' ' HB ' ' A' ' 8' ' ' VAL . 9.7 t80 -70.79 -61.73 1.65 Allowed 'General case' 0 C--N 1.364 1.23 0 CA-C-N 118.764 0.711 . . . . 0.0 111.645 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -56.57 -22.26 32.27 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 47.1 mt-10 -99.22 -50.07 4.26 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 123.231 0.332 . . . . 0.0 110.949 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.405 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 2.1 t70 -71.02 -17.03 62.64 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' A' ' 4' ' ' PHE . 11.1 p -58.78 -27.85 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.45 -13.99 71.51 Favored Glycine 0 C--N 1.344 0.973 0 O-C-N 123.329 0.393 . . . . 0.0 113.8 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 42.4 p -128.79 -24.87 2.91 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 122.404 0.282 . . . . 0.0 111.694 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.405 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 41.7 t30 -53.64 -50.99 64.56 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.127 0.571 . . . . 0.0 111.669 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.514 ' O ' HG13 ' A' ' 15' ' ' ILE . 34.1 mtmt -60.17 -53.08 61.94 Favored 'General case' 0 C--O 1.242 0.689 0 O-C-N 123.484 0.49 . . . . 0.0 110.327 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.92 -30.31 69.56 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.406 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.28 -44.66 24.81 Favored 'General case' 0 C--O 1.239 0.55 0 O-C-N 123.71 0.3 . . . . 0.0 111.146 178.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.3 pt -71.24 -34.48 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -71.8 -44.84 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 CA-C-O 120.767 0.318 . . . . 0.0 110.411 178.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.34 -45.17 49.47 Favored Glycine 0 C--N 1.346 1.107 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.842 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.169 0 C-N-CA 123.849 0.86 . . . . 0.0 111.814 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.456 0 N-CA-C 111.277 0.103 . . . . 0.0 111.277 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.709 HG22 ' H ' ' A' ' 3' ' ' PHE . 4.7 p -118.36 -164.24 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.272 0 O-C-N 123.477 0.486 . . . . 0.0 109.974 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.709 ' H ' HG22 ' A' ' 2' ' ' VAL . 88.3 m-85 -136.33 -18.9 1.48 Allowed 'General case' 0 C--N 1.351 0.65 0 CA-C-N 118.179 0.445 . . . . 0.0 111.625 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -64.48 -47.6 78.37 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 122.843 0.457 . . . . 0.0 111.632 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.47 -25.15 64.17 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -97.53 -52.14 3.88 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.377 179.33 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 3' ' ' PHE . 50.6 m-20 -71.4 -11.14 60.74 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.2 m 28.55 -120.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 178.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.17 -11.87 67.95 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.447 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 70.1 m -81.06 -54.14 5.8 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 122.59 0.356 . . . . 0.0 110.326 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.61 ' O ' HG12 ' A' ' 15' ' ' ILE . 1.4 t-20 41.68 -166.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 124.282 1.033 . . . . 0.0 113.649 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.575 ' O ' HG23 ' A' ' 16' ' ' ILE . 97.2 mttt -48.87 -43.6 39.06 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.066 0.546 . . . . 0.0 111.245 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -51.79 -40.03 48.37 Favored Glycine 0 C--N 1.355 1.62 0 O-C-N 124.309 1.006 . . . . 0.0 113.772 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.447 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -93.98 -34.78 12.92 Favored 'General case' 0 C--O 1.241 0.605 0 CA-C-N 116.847 0.323 . . . . 0.0 110.673 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.61 HG12 ' O ' ' A' ' 11' ' ' ASN . 46.2 mm -63.18 -33.39 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 CA-C-O 119.034 -0.507 . . . . 0.0 112.271 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -84.21 -35.11 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.458 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.474 ' H ' HD13 ' A' ' 16' ' ' ILE . . . -71.3 -43.03 56.03 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.925 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.935 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.717 0.294 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 t -131.16 -65.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.279 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB2' ' OD2' ' A' ' 7' ' ' ASP . 40.0 p90 -144.81 -19.35 0.51 Allowed 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -58.01 -45.0 87.59 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 122.931 0.492 . . . . 0.0 112.221 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -58.1 -36.19 72.52 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.09 -37.95 13.89 Favored 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.432 0.457 . . . . 0.0 111.115 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.492 ' OD2' ' HB2' ' A' ' 3' ' ' PHE . 6.5 m-20 -70.72 -29.68 66.01 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.0 p -62.86 -28.54 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.57 -12.36 69.96 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.412 0.445 . . . . 0.0 113.876 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.7 t -130.64 -50.6 1.06 Allowed 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.778 0.289 . . . . 0.0 111.375 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -57.58 -51.2 70.44 Favored 'General case' 0 N--CA 1.475 0.813 0 O-C-N 123.276 0.36 . . . . 0.0 111.474 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 15' ' ' ILE . 12.1 tptm -60.19 -52.16 66.48 Favored 'General case' 0 C--O 1.242 0.673 0 O-C-N 123.498 0.499 . . . . 0.0 109.915 179.089 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.01 -31.69 73.34 Favored Glycine 0 C--N 1.35 1.327 0 O-C-N 124.013 0.821 . . . . 0.0 112.441 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.36 -44.87 27.89 Favored 'General case' 0 C--O 1.239 0.534 0 C-N-CA 122.324 0.25 . . . . 0.0 111.08 178.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.4 pt -70.92 -34.08 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -72.45 -44.67 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.403 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.65 -44.15 49.96 Favored Glycine 0 C--N 1.345 1.037 0 CA-C-N 115.487 -0.779 . . . . 0.0 112.86 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.84 -179.913 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.563 ' O ' ' HB2' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -130.03 -143.1 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.949 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.43 ' CE2' ' HD2' ' A' ' 4' ' ' PHE . 3.1 t80 81.29 -176.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 125.18 1.392 . . . . 0.0 111.556 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.43 ' HD2' ' CE2' ' A' ' 3' ' ' PHE . 87.9 m-85 -60.52 -57.9 10.78 Favored 'General case' 0 C--N 1.36 1.059 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.091 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.83 -25.68 30.05 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.563 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 43.3 mt-10 -101.69 -41.24 6.63 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 123.196 0.31 . . . . 0.0 111.54 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -70.26 -31.97 69.59 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.628 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 59.0 t -81.73 -27.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 123.16 0.287 . . . . 0.0 110.759 -179.153 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.43 -11.37 68.07 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 123.196 0.31 . . . . 0.0 113.019 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.441 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 67.3 m -128.33 -46.61 1.33 Allowed 'General case' 0 C--O 1.244 0.8 0 C-N-CA 122.843 0.457 . . . . 0.0 110.736 179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.628 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER 45.13 -169.12 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.472 1.109 . . . . 0.0 113.662 179.288 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.585 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 31.4 tttp -48.92 -45.98 42.31 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.521 0.728 . . . . 0.0 111.377 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.7 -47.1 65.51 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 114.979 -1.01 . . . . 0.0 114.271 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.441 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -88.53 -41.46 12.7 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 117.248 0.524 . . . . 0.0 111.735 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.708 HG23 HD12 ' A' ' 16' ' ' ILE . 1.3 tt -63.55 -30.2 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.708 HD12 HG23 ' A' ' 15' ' ' ILE . 1.2 mp -92.3 -36.31 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -70.85 -29.1 69.67 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-N 115.896 -0.593 . . . . 0.0 113.412 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.083 -0.96 . . . . 0.0 110.656 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 111.421 0.156 . . . . 0.0 111.421 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.527 HG13 ' CD2' ' A' ' 3' ' ' PHE . 7.6 p -95.08 -49.8 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 O-C-N 123.42 0.45 . . . . 0.0 110.785 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.527 ' CD2' HG13 ' A' ' 2' ' ' VAL . 18.9 p90 -135.47 -17.79 1.74 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 123.231 0.332 . . . . 0.0 111.651 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -65.28 -44.54 87.69 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.778 0.431 . . . . 0.0 111.58 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -65.61 -23.93 66.94 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.939 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -92.11 -44.57 8.75 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.335 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 3.1 t70 -70.92 -29.31 65.32 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.638 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 m 42.53 -153.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 124.646 1.178 . . . . 0.0 112.59 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 66.87 0.87 Allowed Glycine 0 C--N 1.352 1.453 0 C-N-CA 121.73 -0.272 . . . . 0.0 112.587 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 20.3 t 63.24 66.89 0.69 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.973 0.909 . . . . 0.0 111.418 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.493 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 10.4 t-20 -56.07 -51.98 65.91 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.02 179.6 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -61.51 -49.02 78.4 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 123.562 0.539 . . . . 0.0 110.252 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.14 75.64 Favored Glycine 0 C--N 1.348 1.236 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.048 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.562 ' O ' ' HG ' ' A' ' 18' ' ' LEU . . . -77.25 -50.7 12.31 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 122.394 0.278 . . . . 0.0 111.023 178.176 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.7 pt -68.19 -38.71 80.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 45.0 mm -80.88 -35.35 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.03 -42.65 58.87 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.11 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 14' ' ' ALA . 2.3 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.617 0.246 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.473 HG23 ' H ' ' A' ' 3' ' ' PHE . 2.5 m -144.97 -63.47 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.817 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.473 ' H ' HG23 ' A' ' 2' ' ' VAL . 90.1 m-85 -145.89 -54.91 0.28 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 123.029 0.205 . . . . 0.0 111.445 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.52 ' O ' HG13 ' A' ' 8' ' ' VAL . 41.3 p90 -62.44 -45.47 92.94 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.88 -29.82 30.44 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -100.46 -40.22 7.57 Favored 'General case' 0 CA--C 1.535 0.367 0 O-C-N 123.52 0.512 . . . . 0.0 110.575 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.416 ' O ' ' N ' ' A' ' 11' ' ' ASN . 4.4 m-20 -71.13 -15.95 62.53 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.52 HG13 ' O ' ' A' ' 4' ' ' PHE . 0.7 OUTLIER -55.1 -17.99 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.25 -25.11 76.1 Favored Glycine 0 C--N 1.343 0.934 0 C-N-CA 121.7 -0.286 . . . . 0.0 113.231 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.462 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 75.4 m -140.61 -46.52 0.41 Allowed 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.748 0.419 . . . . 0.0 110.687 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.514 ' O ' HG12 ' A' ' 15' ' ' ILE . 8.3 p30 40.83 -167.94 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 125.117 1.367 . . . . 0.0 114.049 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.432 ' O ' HG22 ' A' ' 16' ' ' ILE . 21.3 tptt -47.43 -47.15 26.9 Favored 'General case' 0 C--N 1.353 0.76 0 C-N-CA 123.451 0.7 . . . . 0.0 111.343 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.24 -44.9 58.04 Favored Glycine 0 C--N 1.35 1.338 0 O-C-N 124.209 0.943 . . . . 0.0 114.302 -179.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.462 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -89.8 -40.92 12.16 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 117.307 0.554 . . . . 0.0 111.83 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 11' ' ' ASN . 5.0 pt -65.84 -27.03 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.432 HG22 ' O ' ' A' ' 12' ' ' LYS . 2.4 tp -87.25 -38.28 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 178.336 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.38 -36.77 63.05 Favored Glycine 0 C--N 1.346 1.128 0 CA-C-N 115.767 -0.651 . . . . 0.0 113.204 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.6 tp . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 117.985 -1.007 . . . . 0.0 111.615 -179.695 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 N--CA 1.467 0.425 0 N-CA-C 111.554 0.205 . . . . 5.71 111.554 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.459 ' O ' HG22 ' A' ' 8' ' ' VAL . 7.6 t80 -60.98 -47.99 83.88 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 122.914 0.486 . . . . 5.4 111.58 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.24 -27.13 65.48 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.095 0.558 . . . . 3.03 112.145 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -92.65 -38.02 12.1 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.945 -0.57 . . . . 4.49 110.323 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -70.87 -29.11 65.13 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 115.974 -0.557 . . . . 3.37 112.482 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 4' ' ' PHE . 5.3 m -62.0 -23.35 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 112.883 0.697 . . . . 3.91 112.883 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.21 -21.75 77.25 Favored Glycine 0 C--N 1.344 0.988 0 O-C-N 123.308 0.38 . . . . 1.89 113.532 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.0 m -123.83 -50.22 1.84 Allowed 'General case' 0 C--O 1.245 0.853 0 CA-C-O 120.868 0.366 . . . . 3.41 110.648 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.561 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.8 t30 45.66 -171.17 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.607 1.163 . . . . 4.17 113.321 179.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.561 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.2 mptm? -47.33 -46.16 25.21 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.237 0.615 . . . . 5.01 111.346 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.31 -45.95 57.76 Favored Glycine 0 C--N 1.35 1.322 0 O-C-N 124.258 0.974 . . . . 1.65 114.201 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -89.71 -39.09 13.39 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-N 117.321 0.56 . . . . 1.74 111.879 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 11' ' ' ASN . 3.3 pt -67.12 -25.83 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 N-CA-C 112.278 0.473 . . . . 3.36 112.278 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.9 tp -80.72 -42.09 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.974 -0.38 . . . . 3.76 109.974 178.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.52 -42.98 54.35 Favored Glycine 0 C--N 1.346 1.087 0 CA-C-N 115.701 -0.681 . . . . 2.16 112.895 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.7 mt . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.152 -0.928 . . . . 4.42 110.837 -179.917 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.491 ' O ' HG13 ' A' ' 8' ' ' VAL . 31.7 p90 -59.23 -43.37 92.37 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 112.392 0.515 . . . . 0.0 112.392 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.41 -28.34 53.53 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.142 0.577 . . . . 0.0 112.408 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -100.71 -35.75 9.36 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.131 178.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.89 -22.24 62.3 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.579 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.491 HG13 ' O ' ' A' ' 4' ' ' PHE . 1.8 m -56.09 -29.0 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.53 -13.46 71.23 Favored Glycine 0 C--N 1.342 0.913 0 O-C-N 123.244 0.34 . . . . 0.0 113.527 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 29.0 m -128.57 -57.32 1.2 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 122.649 0.38 . . . . 0.0 110.525 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 18.0 -120.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 125.704 1.602 . . . . 0.0 115.085 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.64 ' HA ' HG22 ' A' ' 15' ' ' ILE . 8.5 tptm -59.67 -51.05 71.45 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.609 0.764 . . . . 0.0 112.479 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.13 -31.06 48.46 Favored Glycine 0 C--N 1.35 1.345 0 O-C-N 123.828 0.705 . . . . 0.0 113.839 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -93.22 -41.01 10.13 Favored 'General case' 0 C--O 1.24 0.576 0 O-C-N 123.634 0.255 . . . . 0.0 111.047 178.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.64 HG22 ' HA ' ' A' ' 12' ' ' LYS . 1.0 OUTLIER -66.62 -30.28 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.345 0.403 . . . . 0.0 111.699 -179.79 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.446 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.4 tp -81.21 -40.8 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.785 0 O-C-N 123.201 0.313 . . . . 0.0 110.165 178.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.36 -41.83 57.97 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.936 178.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 mp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.836 -179.884 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.7 p90 . . . . . 0 N--CA 1.478 0.953 0 N-CA-C 111.589 0.218 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -60.3 -47.87 84.19 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 122.963 0.505 . . . . 0.0 112.041 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.18 -27.34 67.05 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -92.59 -42.81 9.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.677 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -70.93 -28.47 64.53 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.62 -23.86 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.38 -18.81 75.56 Favored Glycine 0 C--N 1.343 0.934 0 CA-C-O 119.895 -0.391 . . . . 0.0 113.881 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.4 m -133.53 -45.84 0.82 Allowed 'General case' 0 C--O 1.238 0.461 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.461 ' O ' ' HB ' ' A' ' 15' ' ' ILE . 3.0 t30 -57.97 -48.11 80.96 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.753 0.421 . . . . 0.0 111.752 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.464 ' HA ' HG22 ' A' ' 15' ' ' ILE . 12.4 tptp -65.04 -50.48 66.05 Favored 'General case' 0 C--O 1.241 0.612 0 O-C-N 123.3 0.375 . . . . 0.0 110.095 179.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.95 -34.49 83.42 Favored Glycine 0 C--N 1.35 1.36 0 O-C-N 123.946 0.779 . . . . 0.0 112.498 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.36 -39.98 31.32 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 122.256 0.223 . . . . 0.0 110.634 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.464 HG22 ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -68.47 -35.1 69.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.376 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -74.48 -43.89 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-O 120.623 0.249 . . . . 0.0 110.664 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.35 -42.38 56.92 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.009 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.587 -179.795 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 p90 . . . . . 0 CA--C 1.544 0.717 0 CA-C-O 120.893 0.378 . . . . 0.0 111.265 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -61.65 -39.93 93.09 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.113 0.565 . . . . 0.0 111.782 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.06 -31.19 68.65 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.891 0.477 . . . . 0.0 111.822 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -95.03 -34.59 12.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.263 178.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -26.78 63.71 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.834 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 9' ' ' GLY . 3.9 p 52.58 -149.7 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 C-N-CA 124.289 1.036 . . . . 0.0 110.944 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.541 ' H ' HG22 ' A' ' 8' ' ' VAL . . . -59.54 -55.77 28.7 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 118.361 0.528 . . . . 0.0 113.244 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.491 ' H ' ' HB2' ' A' ' 14' ' ' ALA . 50.4 m -152.78 45.21 0.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 122.419 0.288 . . . . 0.0 111.045 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.683 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.9 p-10 23.93 -100.85 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.683 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.0 OUTLIER -60.67 -53.81 52.86 Favored 'General case' 0 C--N 1.354 0.781 0 C-N-CA 123.226 0.61 . . . . 0.0 110.597 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.09 -27.93 63.21 Favored Glycine 0 C--N 1.349 1.276 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.609 178.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB2' ' H ' ' A' ' 10' ' ' SER . . . -80.41 -48.61 12.63 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 122.286 0.235 . . . . 0.0 110.674 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 12' ' ' LYS . 2.2 pp -66.74 -41.35 87.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.3 tp -81.24 -35.1 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 178.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.13 -38.02 63.59 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.759 -0.655 . . . . 0.0 113.217 178.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.9 tt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.535 -179.87 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 . . . . . 0 N--CA 1.486 1.339 0 N-CA-C 112.47 0.545 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.5 ' O ' HG13 ' A' ' 8' ' ' VAL . 46.0 p90 -57.03 -45.78 82.87 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.53 -28.58 55.64 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -98.94 -39.37 8.6 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.081 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -70.81 -20.39 62.58 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.601 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 1.4 m -55.53 -31.51 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.59 -16.67 74.14 Favored Glycine 0 CA--C 1.529 0.945 0 O-C-N 123.411 0.444 . . . . 0.0 113.642 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 63.2 m -119.99 -56.35 2.02 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.484 0.314 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.601 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER 43.34 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.756 1.222 . . . . 0.0 113.867 179.161 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.0 mmtp -50.81 -39.61 53.51 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 123.147 0.579 . . . . 0.0 111.457 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.65 -46.29 75.21 Favored Glycine 0 C--N 1.351 1.383 0 O-C-N 123.979 0.799 . . . . 0.0 113.259 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.82 -37.15 16.8 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.691 0.245 . . . . 0.0 110.927 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.7 mt -64.22 -27.75 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 123.205 0.316 . . . . 0.0 111.212 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 3.5 tp -79.93 -42.36 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.33 -43.98 53.22 Favored Glycine 0 C--N 1.345 1.051 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.989 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.6 tp . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.495 -0.764 . . . . 0.0 110.565 -179.907 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 . . . . . 0 N--CA 1.488 1.457 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.48 ' O ' ' HB ' ' A' ' 8' ' ' VAL . 9.7 t80 -70.79 -61.73 1.65 Allowed 'General case' 0 C--N 1.364 1.23 0 CA-C-N 118.764 0.711 . . . . 0.0 111.645 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -56.57 -22.26 32.27 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -99.22 -50.07 4.26 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 123.231 0.332 . . . . 0.0 110.949 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.405 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 2.1 t70 -71.02 -17.03 62.64 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' A' ' 4' ' ' PHE . 11.1 p -58.78 -27.85 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.45 -13.99 71.51 Favored Glycine 0 C--N 1.344 0.973 0 O-C-N 123.329 0.393 . . . . 0.0 113.8 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 42.4 p -128.79 -24.87 2.91 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 122.404 0.282 . . . . 0.0 111.694 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.405 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 41.7 t30 -53.64 -50.99 64.56 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.127 0.571 . . . . 0.0 111.669 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.514 ' O ' HG13 ' A' ' 15' ' ' ILE . 34.1 mtmt -60.17 -53.08 61.94 Favored 'General case' 0 C--O 1.242 0.689 0 O-C-N 123.484 0.49 . . . . 0.0 110.327 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.92 -30.31 69.56 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.406 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.28 -44.66 24.81 Favored 'General case' 0 C--O 1.239 0.55 0 O-C-N 123.71 0.3 . . . . 0.0 111.146 178.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.3 pt -71.24 -34.48 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -71.8 -44.84 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 CA-C-O 120.767 0.318 . . . . 0.0 110.411 178.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.34 -45.17 49.47 Favored Glycine 0 C--N 1.346 1.107 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.842 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.169 0 C-N-CA 123.849 0.86 . . . . 0.0 111.814 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.531 ' HB3' ' OD2' ' A' ' 7' ' ' ASP . 88.3 m-85 . . . . . 0 N--CA 1.469 0.499 0 N-CA-C 111.625 0.232 . . . . 0.0 111.625 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -64.48 -47.6 78.37 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 122.843 0.457 . . . . 0.0 111.632 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.47 -25.15 64.17 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -97.53 -52.14 3.88 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.377 179.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 3' ' ' PHE . 50.6 m-20 -71.4 -11.14 60.74 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.2 m 28.55 -120.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 178.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.17 -11.87 67.95 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.447 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 70.1 m -81.06 -54.14 5.8 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 122.59 0.356 . . . . 0.0 110.326 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.643 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.3 t30 41.68 -166.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 124.282 1.033 . . . . 0.0 113.649 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.643 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 97.2 mttt -48.87 -43.6 39.06 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.066 0.546 . . . . 0.0 111.245 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -51.79 -40.03 48.37 Favored Glycine 0 C--N 1.355 1.62 0 O-C-N 124.309 1.006 . . . . 0.0 113.772 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.447 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -93.98 -34.78 12.92 Favored 'General case' 0 C--O 1.241 0.605 0 CA-C-N 116.847 0.323 . . . . 0.0 110.673 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.61 HG12 ' O ' ' A' ' 11' ' ' ASN . 46.2 mm -63.18 -33.39 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 CA-C-O 119.034 -0.507 . . . . 0.0 112.271 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -84.21 -35.11 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.458 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.474 ' H ' HD13 ' A' ' 16' ' ' ILE . . . -71.3 -43.03 56.03 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.925 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.935 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB2' ' OD2' ' A' ' 7' ' ' ASP . 40.0 p90 . . . . . 0 N--CA 1.473 0.689 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -58.01 -45.0 87.59 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 122.931 0.492 . . . . 0.0 112.221 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -58.1 -36.19 72.52 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.09 -37.95 13.89 Favored 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.432 0.457 . . . . 0.0 111.115 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.492 ' OD2' ' HB2' ' A' ' 3' ' ' PHE . 6.5 m-20 -70.72 -29.68 66.01 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.0 p -62.86 -28.54 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.57 -12.36 69.96 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.412 0.445 . . . . 0.0 113.876 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.7 t -130.64 -50.6 1.06 Allowed 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.778 0.289 . . . . 0.0 111.375 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -57.58 -51.2 70.44 Favored 'General case' 0 N--CA 1.475 0.813 0 O-C-N 123.276 0.36 . . . . 0.0 111.474 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 15' ' ' ILE . 12.1 tptm -60.19 -52.16 66.48 Favored 'General case' 0 C--O 1.242 0.673 0 O-C-N 123.498 0.499 . . . . 0.0 109.915 179.089 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.01 -31.69 73.34 Favored Glycine 0 C--N 1.35 1.327 0 O-C-N 124.013 0.821 . . . . 0.0 112.441 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.36 -44.87 27.89 Favored 'General case' 0 C--O 1.239 0.534 0 C-N-CA 122.324 0.25 . . . . 0.0 111.08 178.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.4 pt -70.92 -34.08 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -72.45 -44.67 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.403 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.65 -44.15 49.96 Favored Glycine 0 C--N 1.345 1.037 0 CA-C-N 115.487 -0.779 . . . . 0.0 112.86 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.84 -179.913 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . 0.43 ' CE2' ' HD2' ' A' ' 4' ' ' PHE . 3.1 t80 . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 119.603 -0.237 . . . . 0.0 111.556 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.43 ' HD2' ' CE2' ' A' ' 3' ' ' PHE . 87.9 m-85 -60.52 -57.9 10.78 Favored 'General case' 0 C--N 1.36 1.059 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.091 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.83 -25.68 30.05 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -101.69 -41.24 6.63 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 123.196 0.31 . . . . 0.0 111.54 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -70.26 -31.97 69.59 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.628 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 59.0 t -81.73 -27.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 123.16 0.287 . . . . 0.0 110.759 -179.153 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.43 -11.37 68.07 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 123.196 0.31 . . . . 0.0 113.019 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.441 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 67.3 m -128.33 -46.61 1.33 Allowed 'General case' 0 C--O 1.244 0.8 0 C-N-CA 122.843 0.457 . . . . 0.0 110.736 179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.628 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER 45.13 -169.12 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.472 1.109 . . . . 0.0 113.662 179.288 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.585 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 31.4 tttp -48.92 -45.98 42.31 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.521 0.728 . . . . 0.0 111.377 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.7 -47.1 65.51 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 114.979 -1.01 . . . . 0.0 114.271 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.441 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -88.53 -41.46 12.7 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 117.248 0.524 . . . . 0.0 111.735 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.708 HG23 HD12 ' A' ' 16' ' ' ILE . 1.3 tt -63.55 -30.2 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.708 HD12 HG23 ' A' ' 15' ' ' ILE . 1.2 mp -92.3 -36.31 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -70.85 -29.1 69.67 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-N 115.896 -0.593 . . . . 0.0 113.412 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.083 -0.96 . . . . 0.0 110.656 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 18.9 p90 . . . . . 0 N--CA 1.471 0.607 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -65.28 -44.54 87.69 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.778 0.431 . . . . 0.0 111.58 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -65.61 -23.93 66.94 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.939 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -92.11 -44.57 8.75 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.335 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 3.1 t70 -70.92 -29.31 65.32 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.638 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 m 42.53 -153.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 124.646 1.178 . . . . 0.0 112.59 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 66.87 0.87 Allowed Glycine 0 C--N 1.352 1.453 0 C-N-CA 121.73 -0.272 . . . . 0.0 112.587 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 20.3 t 63.24 66.89 0.69 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.973 0.909 . . . . 0.0 111.418 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.493 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 10.4 t-20 -56.07 -51.98 65.91 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.02 179.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -61.51 -49.02 78.4 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 123.562 0.539 . . . . 0.0 110.252 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.14 75.64 Favored Glycine 0 C--N 1.348 1.236 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.048 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.562 ' O ' ' HG ' ' A' ' 18' ' ' LEU . . . -77.25 -50.7 12.31 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 122.394 0.278 . . . . 0.0 111.023 178.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.7 pt -68.19 -38.71 80.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 45.0 mm -80.88 -35.35 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.03 -42.65 58.87 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.11 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 14' ' ' ALA . 2.3 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 . . . . . 0 N--CA 1.471 0.583 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.52 ' O ' HG13 ' A' ' 8' ' ' VAL . 41.3 p90 -62.44 -45.47 92.94 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.88 -29.82 30.44 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -100.46 -40.22 7.57 Favored 'General case' 0 CA--C 1.535 0.367 0 O-C-N 123.52 0.512 . . . . 0.0 110.575 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.416 ' O ' ' N ' ' A' ' 11' ' ' ASN . 4.4 m-20 -71.13 -15.95 62.53 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.52 HG13 ' O ' ' A' ' 4' ' ' PHE . 0.7 OUTLIER -55.1 -17.99 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.25 -25.11 76.1 Favored Glycine 0 C--N 1.343 0.934 0 C-N-CA 121.7 -0.286 . . . . 0.0 113.231 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.462 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 75.4 m -140.61 -46.52 0.41 Allowed 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.748 0.419 . . . . 0.0 110.687 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.514 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.6 p-10 40.83 -167.94 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 125.117 1.367 . . . . 0.0 114.049 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.432 ' O ' HG22 ' A' ' 16' ' ' ILE . 21.3 tptt -47.43 -47.15 26.9 Favored 'General case' 0 C--N 1.353 0.76 0 C-N-CA 123.451 0.7 . . . . 0.0 111.343 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.425 ' H ' ' ND2' ' A' ' 11' ' ' ASN . . . -52.24 -44.9 58.04 Favored Glycine 0 C--N 1.35 1.338 0 O-C-N 124.209 0.943 . . . . 0.0 114.302 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.462 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -89.8 -40.92 12.16 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 117.307 0.554 . . . . 0.0 111.83 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 11' ' ' ASN . 5.0 pt -65.84 -27.03 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.432 HG22 ' O ' ' A' ' 12' ' ' LYS . 2.4 tp -87.25 -38.28 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 178.336 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.38 -36.77 63.05 Favored Glycine 0 C--N 1.346 1.128 0 CA-C-N 115.767 -0.651 . . . . 0.0 113.204 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.6 tp . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 117.985 -1.007 . . . . 0.0 111.615 -179.695 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.24 0.067 . . . . 6.72 110.967 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.463 HG12 ' H ' ' A' ' 3' ' ' PHE . 0.7 OUTLIER -113.04 -154.34 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 O-C-N 123.447 0.467 . . . . 3.84 109.756 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.463 ' H ' HG12 ' A' ' 2' ' ' VAL . 90.2 m-85 -131.03 -19.56 2.85 Favored 'General case' 0 C--N 1.347 0.468 0 C-N-CA 122.23 0.212 . . . . 5.71 111.554 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.459 ' O ' HG22 ' A' ' 8' ' ' VAL . 7.6 t80 -60.98 -47.99 83.88 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 122.914 0.486 . . . . 5.4 111.58 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.24 -27.13 65.48 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.095 0.558 . . . . 3.03 112.145 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -92.65 -38.02 12.1 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.945 -0.57 . . . . 4.49 110.323 178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -70.87 -29.11 65.13 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-N 115.974 -0.557 . . . . 3.37 112.482 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 4' ' ' PHE . 5.3 m -62.0 -23.35 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 112.883 0.697 . . . . 3.91 112.883 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.21 -21.75 77.25 Favored Glycine 0 C--N 1.344 0.988 0 O-C-N 123.308 0.38 . . . . 1.89 113.532 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.0 m -123.83 -50.22 1.84 Allowed 'General case' 0 C--O 1.245 0.853 0 CA-C-O 120.868 0.366 . . . . 3.41 110.648 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.561 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.8 t30 45.66 -171.17 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.607 1.163 . . . . 4.17 113.321 179.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.561 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.2 mptm? -47.33 -46.16 25.21 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.237 0.615 . . . . 5.01 111.346 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -52.31 -45.95 57.76 Favored Glycine 0 C--N 1.35 1.322 0 O-C-N 124.258 0.974 . . . . 1.65 114.201 -179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -89.71 -39.09 13.39 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-N 117.321 0.56 . . . . 1.74 111.879 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 11' ' ' ASN . 3.3 pt -67.12 -25.83 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 N-CA-C 112.278 0.473 . . . . 3.36 112.278 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.9 tp -80.72 -42.09 20.37 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.974 -0.38 . . . . 3.76 109.974 178.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.52 -42.98 54.35 Favored Glycine 0 C--N 1.346 1.087 0 CA-C-N 115.701 -0.681 . . . . 2.16 112.895 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.7 mt . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.152 -0.928 . . . . 4.42 110.837 -179.917 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 N--CA 1.488 1.472 0 CA-C-O 120.366 0.126 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.457 HG23 ' CD2' ' A' ' 3' ' ' PHE . 6.7 m -137.9 -151.42 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.517 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.457 ' CD2' HG23 ' A' ' 2' ' ' VAL . 99.4 m-85 63.82 21.13 12.54 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 123.572 0.749 . . . . 0.0 112.052 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.491 ' O ' HG13 ' A' ' 8' ' ' VAL . 31.7 p90 -59.23 -43.37 92.37 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 112.392 0.515 . . . . 0.0 112.392 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.41 -28.34 53.53 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.142 0.577 . . . . 0.0 112.408 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -100.71 -35.75 9.36 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.131 178.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.89 -22.24 62.3 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.579 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.491 HG13 ' O ' ' A' ' 4' ' ' PHE . 1.8 m -56.09 -29.0 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.53 -13.46 71.23 Favored Glycine 0 C--N 1.342 0.913 0 O-C-N 123.244 0.34 . . . . 0.0 113.527 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 29.0 m -128.57 -57.32 1.2 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 122.649 0.38 . . . . 0.0 110.525 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 18.0 -120.01 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 125.704 1.602 . . . . 0.0 115.085 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.64 ' HA ' HG22 ' A' ' 15' ' ' ILE . 8.5 tptm -59.67 -51.05 71.45 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.609 0.764 . . . . 0.0 112.479 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.13 -31.06 48.46 Favored Glycine 0 C--N 1.35 1.345 0 O-C-N 123.828 0.705 . . . . 0.0 113.839 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -93.22 -41.01 10.13 Favored 'General case' 0 C--O 1.24 0.576 0 O-C-N 123.634 0.255 . . . . 0.0 111.047 178.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.64 HG22 ' HA ' ' A' ' 12' ' ' LYS . 1.0 OUTLIER -66.62 -30.28 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.345 0.403 . . . . 0.0 111.699 -179.79 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.446 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.4 tp -81.21 -40.8 18.61 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.785 0 O-C-N 123.201 0.313 . . . . 0.0 110.165 178.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.36 -41.83 57.97 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.936 178.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.8 mp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.836 -179.884 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.622 0.248 . . . . 0.0 110.698 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.583 HG12 ' CD2' ' A' ' 3' ' ' PHE . 2.6 t 60.55 -88.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 123.883 0.873 . . . . 0.0 111.129 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.583 ' CD2' HG12 ' A' ' 2' ' ' VAL . 9.7 p90 -161.58 -27.2 0.05 Allowed 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.785 0.434 . . . . 0.0 111.589 179.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -60.3 -47.87 84.19 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 122.963 0.505 . . . . 0.0 112.041 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.18 -27.34 67.05 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -92.59 -42.81 9.46 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.677 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -70.93 -28.47 64.53 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.3 p -59.62 -23.86 27.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.38 -18.81 75.56 Favored Glycine 0 C--N 1.343 0.934 0 CA-C-O 119.895 -0.391 . . . . 0.0 113.881 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 55.4 m -133.53 -45.84 0.82 Allowed 'General case' 0 C--O 1.238 0.461 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.461 ' O ' ' HB ' ' A' ' 15' ' ' ILE . 3.0 t30 -57.97 -48.11 80.96 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.753 0.421 . . . . 0.0 111.752 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.464 ' HA ' HG22 ' A' ' 15' ' ' ILE . 12.4 tptp -65.04 -50.48 66.05 Favored 'General case' 0 C--O 1.241 0.612 0 O-C-N 123.3 0.375 . . . . 0.0 110.095 179.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.95 -34.49 83.42 Favored Glycine 0 C--N 1.35 1.36 0 O-C-N 123.946 0.779 . . . . 0.0 112.498 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -79.36 -39.98 31.32 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 122.256 0.223 . . . . 0.0 110.634 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.464 HG22 ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -68.47 -35.1 69.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.376 179.748 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -74.48 -43.89 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-O 120.623 0.249 . . . . 0.0 110.664 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.35 -42.38 56.92 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.009 178.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.0 tp . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.587 -179.795 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.7 tp . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.29 0.091 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 5.7 m -97.92 -159.95 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 123.366 0.416 . . . . 0.0 110.977 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 p90 -115.04 22.13 13.65 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 120.893 0.378 . . . . 0.0 111.265 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -61.65 -39.93 93.09 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.113 0.565 . . . . 0.0 111.782 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.06 -31.19 68.65 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.891 0.477 . . . . 0.0 111.822 179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -95.03 -34.59 12.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.263 178.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -26.78 63.71 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.834 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 9' ' ' GLY . 3.9 p 52.58 -149.7 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 C-N-CA 124.289 1.036 . . . . 0.0 110.944 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.541 ' H ' HG22 ' A' ' 8' ' ' VAL . . . -59.54 -55.77 28.7 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 118.361 0.528 . . . . 0.0 113.244 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.491 ' H ' ' HB2' ' A' ' 14' ' ' ALA . 50.4 m -152.78 45.21 0.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 122.419 0.288 . . . . 0.0 111.045 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.683 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.9 p-10 23.93 -100.85 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.683 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 1.0 OUTLIER -60.67 -53.81 52.86 Favored 'General case' 0 C--N 1.354 0.781 0 C-N-CA 123.226 0.61 . . . . 0.0 110.597 -179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.09 -27.93 63.21 Favored Glycine 0 C--N 1.349 1.276 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.609 178.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB2' ' H ' ' A' ' 10' ' ' SER . . . -80.41 -48.61 12.63 Favored 'General case' 0 C--O 1.239 0.545 0 C-N-CA 122.286 0.235 . . . . 0.0 110.674 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 12' ' ' LYS . 2.2 pp -66.74 -41.35 87.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 12' ' ' LYS . 3.3 tp -81.24 -35.1 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 178.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.13 -38.02 63.59 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.759 -0.655 . . . . 0.0 113.217 178.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.9 tt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.535 -179.87 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 12.3 mt . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.85 -51.05 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 O-C-N 123.349 0.405 . . . . 0.0 111.592 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 54.9 30.91 14.77 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 123.67 0.788 . . . . 0.0 112.47 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.5 ' O ' HG13 ' A' ' 8' ' ' VAL . 46.0 p90 -57.03 -45.78 82.87 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -55.53 -28.58 55.64 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -98.94 -39.37 8.6 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.081 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -70.81 -20.39 62.58 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.601 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 1.4 m -55.53 -31.51 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.59 -16.67 74.14 Favored Glycine 0 CA--C 1.529 0.945 0 O-C-N 123.411 0.444 . . . . 0.0 113.642 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 63.2 m -119.99 -56.35 2.02 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.484 0.314 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.601 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER 43.34 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.756 1.222 . . . . 0.0 113.867 179.161 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.0 mmtp -50.81 -39.61 53.51 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 123.147 0.579 . . . . 0.0 111.457 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.65 -46.29 75.21 Favored Glycine 0 C--N 1.351 1.383 0 O-C-N 123.979 0.799 . . . . 0.0 113.259 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.82 -37.15 16.8 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.691 0.245 . . . . 0.0 110.927 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.7 mt -64.22 -27.75 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 123.205 0.316 . . . . 0.0 111.212 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 3.5 tp -79.93 -42.36 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.33 -43.98 53.22 Favored Glycine 0 C--N 1.345 1.051 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.989 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.6 tp . . . . . 0 C--O 1.251 1.143 0 CA-C-O 118.495 -0.764 . . . . 0.0 110.565 -179.907 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 N--CA 1.488 1.454 0 CA-C-O 120.367 0.127 . . . . 0.0 111.15 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.58 ' O ' ' HB2' ' A' ' 6' ' ' GLU . 1.5 t 55.55 -146.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 C-N-CA 123.856 0.862 . . . . 0.0 110.804 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.473 ' H ' HG12 ' A' ' 2' ' ' VAL . 94.5 m-85 59.53 164.98 0.05 Allowed 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 124.655 1.182 . . . . 0.0 112.589 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.48 ' O ' ' HB ' ' A' ' 8' ' ' VAL . 9.7 t80 -70.79 -61.73 1.65 Allowed 'General case' 0 C--N 1.364 1.23 0 CA-C-N 118.764 0.711 . . . . 0.0 111.645 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -56.57 -22.26 32.27 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 47.1 mt-10 -99.22 -50.07 4.26 Favored 'General case' 0 CA--C 1.533 0.295 0 O-C-N 123.231 0.332 . . . . 0.0 110.949 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.405 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 2.1 t70 -71.02 -17.03 62.64 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' A' ' 4' ' ' PHE . 11.1 p -58.78 -27.85 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.45 -13.99 71.51 Favored Glycine 0 C--N 1.344 0.973 0 O-C-N 123.329 0.393 . . . . 0.0 113.8 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 42.4 p -128.79 -24.87 2.91 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 122.404 0.282 . . . . 0.0 111.694 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.405 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 41.7 t30 -53.64 -50.99 64.56 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.127 0.571 . . . . 0.0 111.669 -179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.514 ' O ' HG13 ' A' ' 15' ' ' ILE . 34.1 mtmt -60.17 -53.08 61.94 Favored 'General case' 0 C--O 1.242 0.689 0 O-C-N 123.484 0.49 . . . . 0.0 110.327 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.92 -30.31 69.56 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.406 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -78.28 -44.66 24.81 Favored 'General case' 0 C--O 1.239 0.55 0 O-C-N 123.71 0.3 . . . . 0.0 111.146 178.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.3 pt -71.24 -34.48 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -71.8 -44.84 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 CA-C-O 120.767 0.318 . . . . 0.0 110.411 178.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.34 -45.17 49.47 Favored Glycine 0 C--N 1.346 1.107 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.842 178.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.169 0 C-N-CA 123.849 0.86 . . . . 0.0 111.814 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.456 0 N-CA-C 111.277 0.103 . . . . 0.0 111.277 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.709 HG22 ' H ' ' A' ' 3' ' ' PHE . 4.7 p -118.36 -164.24 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.272 0 O-C-N 123.477 0.486 . . . . 0.0 109.974 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.709 ' H ' HG22 ' A' ' 2' ' ' VAL . 88.3 m-85 -136.33 -18.9 1.48 Allowed 'General case' 0 C--N 1.351 0.65 0 CA-C-N 118.179 0.445 . . . . 0.0 111.625 -179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -64.48 -47.6 78.37 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 122.843 0.457 . . . . 0.0 111.632 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -59.47 -25.15 64.17 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -97.53 -52.14 3.88 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.377 179.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 3' ' ' PHE . 50.6 m-20 -71.4 -11.14 60.74 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 5.2 m 28.55 -120.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 178.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.17 -11.87 67.95 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.447 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 70.1 m -81.06 -54.14 5.8 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 122.59 0.356 . . . . 0.0 110.326 179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.643 ' ND2' ' H ' ' A' ' 12' ' ' LYS . 2.3 t30 41.68 -166.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 124.282 1.033 . . . . 0.0 113.649 178.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.643 ' H ' ' ND2' ' A' ' 11' ' ' ASN . 97.2 mttt -48.87 -43.6 39.06 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.066 0.546 . . . . 0.0 111.245 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -51.79 -40.03 48.37 Favored Glycine 0 C--N 1.355 1.62 0 O-C-N 124.309 1.006 . . . . 0.0 113.772 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.447 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -93.98 -34.78 12.92 Favored 'General case' 0 C--O 1.241 0.605 0 CA-C-N 116.847 0.323 . . . . 0.0 110.673 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.61 HG12 ' O ' ' A' ' 11' ' ' ASN . 46.2 mm -63.18 -33.39 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 CA-C-O 119.034 -0.507 . . . . 0.0 112.271 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.575 HG23 ' O ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -84.21 -35.11 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 C-N-CA 119.993 -0.683 . . . . 0.0 110.458 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.474 ' H ' HD13 ' A' ' 16' ' ' ILE . . . -71.3 -43.03 56.03 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.925 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.935 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.717 0.294 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 t -131.16 -65.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.279 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB2' ' OD2' ' A' ' 7' ' ' ASP . 40.0 p90 -144.81 -19.35 0.51 Allowed 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -58.01 -45.0 87.59 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 122.931 0.492 . . . . 0.0 112.221 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -58.1 -36.19 72.52 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.09 -37.95 13.89 Favored 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.432 0.457 . . . . 0.0 111.115 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.492 ' OD2' ' HB2' ' A' ' 3' ' ' PHE . 6.5 m-20 -70.72 -29.68 66.01 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.0 p -62.86 -28.54 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.57 -12.36 69.96 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.412 0.445 . . . . 0.0 113.876 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.7 t -130.64 -50.6 1.06 Allowed 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.778 0.289 . . . . 0.0 111.375 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -57.58 -51.2 70.44 Favored 'General case' 0 N--CA 1.475 0.813 0 O-C-N 123.276 0.36 . . . . 0.0 111.474 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 15' ' ' ILE . 12.1 tptm -60.19 -52.16 66.48 Favored 'General case' 0 C--O 1.242 0.673 0 O-C-N 123.498 0.499 . . . . 0.0 109.915 179.089 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.01 -31.69 73.34 Favored Glycine 0 C--N 1.35 1.327 0 O-C-N 124.013 0.821 . . . . 0.0 112.441 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.36 -44.87 27.89 Favored 'General case' 0 C--O 1.239 0.534 0 C-N-CA 122.324 0.25 . . . . 0.0 111.08 178.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 1.4 pt -70.92 -34.08 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 2.3 pp -72.45 -44.67 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.403 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.65 -44.15 49.96 Favored Glycine 0 C--N 1.345 1.037 0 CA-C-N 115.487 -0.779 . . . . 0.0 112.86 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.84 -179.913 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.563 ' O ' ' HB2' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -130.03 -143.1 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.949 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.43 ' CE2' ' HD2' ' A' ' 4' ' ' PHE . 3.1 t80 81.29 -176.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 125.18 1.392 . . . . 0.0 111.556 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.43 ' HD2' ' CE2' ' A' ' 3' ' ' PHE . 87.9 m-85 -60.52 -57.9 10.78 Favored 'General case' 0 C--N 1.36 1.059 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -177.091 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -54.83 -25.68 30.05 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.563 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 43.3 mt-10 -101.69 -41.24 6.63 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 123.196 0.31 . . . . 0.0 111.54 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -70.26 -31.97 69.59 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.628 ' HA ' ' OD1' ' A' ' 11' ' ' ASN . 59.0 t -81.73 -27.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 O-C-N 123.16 0.287 . . . . 0.0 110.759 -179.153 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.43 -11.37 68.07 Favored Glycine 0 C--N 1.344 1.004 0 O-C-N 123.196 0.31 . . . . 0.0 113.019 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.441 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 67.3 m -128.33 -46.61 1.33 Allowed 'General case' 0 C--O 1.244 0.8 0 C-N-CA 122.843 0.457 . . . . 0.0 110.736 179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.628 ' OD1' ' HA ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER 45.13 -169.12 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.472 1.109 . . . . 0.0 113.662 179.288 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.585 ' O ' ' HB ' ' A' ' 16' ' ' ILE . 31.4 tttp -48.92 -45.98 42.31 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.521 0.728 . . . . 0.0 111.377 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.7 -47.1 65.51 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 114.979 -1.01 . . . . 0.0 114.271 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.441 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -88.53 -41.46 12.7 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 117.248 0.524 . . . . 0.0 111.735 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.708 HG23 HD12 ' A' ' 16' ' ' ILE . 1.3 tt -63.55 -30.2 49.24 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.708 HD12 HG23 ' A' ' 15' ' ' ILE . 1.2 mp -92.3 -36.31 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -70.85 -29.1 69.67 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-N 115.896 -0.593 . . . . 0.0 113.412 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.083 -0.96 . . . . 0.0 110.656 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 111.421 0.156 . . . . 0.0 111.421 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.527 HG13 ' CD2' ' A' ' 3' ' ' PHE . 7.6 p -95.08 -49.8 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 O-C-N 123.42 0.45 . . . . 0.0 110.785 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.527 ' CD2' HG13 ' A' ' 2' ' ' VAL . 18.9 p90 -135.47 -17.79 1.74 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 123.231 0.332 . . . . 0.0 111.651 179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -65.28 -44.54 87.69 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.778 0.431 . . . . 0.0 111.58 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -65.61 -23.93 66.94 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.939 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -92.11 -44.57 8.75 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.335 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' A' ' 11' ' ' ASN . 3.1 t70 -70.92 -29.31 65.32 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.638 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 m 42.53 -153.22 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 124.646 1.178 . . . . 0.0 112.59 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 66.87 0.87 Allowed Glycine 0 C--N 1.352 1.453 0 C-N-CA 121.73 -0.272 . . . . 0.0 112.587 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 20.3 t 63.24 66.89 0.69 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.973 0.909 . . . . 0.0 111.418 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.493 ' HB2' ' O ' ' A' ' 7' ' ' ASP . 10.4 t-20 -56.07 -51.98 65.91 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.02 179.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -61.51 -49.02 78.4 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 123.562 0.539 . . . . 0.0 110.252 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.53 -30.14 75.64 Favored Glycine 0 C--N 1.348 1.236 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.048 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.562 ' O ' ' HG ' ' A' ' 18' ' ' LEU . . . -77.25 -50.7 12.31 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 122.394 0.278 . . . . 0.0 111.023 178.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 1.7 pt -68.19 -38.71 80.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 45.0 mm -80.88 -35.35 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.03 -42.65 58.87 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.11 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 14' ' ' ALA . 2.3 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.076 -0.964 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.617 0.246 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.473 HG23 ' H ' ' A' ' 3' ' ' PHE . 2.5 m -144.97 -63.47 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.817 179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.473 ' H ' HG23 ' A' ' 2' ' ' VAL . 90.1 m-85 -145.89 -54.91 0.28 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 123.029 0.205 . . . . 0.0 111.445 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.52 ' O ' HG13 ' A' ' 8' ' ' VAL . 41.3 p90 -62.44 -45.47 92.94 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -52.88 -29.82 30.44 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -100.46 -40.22 7.57 Favored 'General case' 0 CA--C 1.535 0.367 0 O-C-N 123.52 0.512 . . . . 0.0 110.575 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.416 ' O ' ' N ' ' A' ' 11' ' ' ASN . 4.4 m-20 -71.13 -15.95 62.53 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.52 HG13 ' O ' ' A' ' 4' ' ' PHE . 0.7 OUTLIER -55.1 -17.99 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.25 -25.11 76.1 Favored Glycine 0 C--N 1.343 0.934 0 C-N-CA 121.7 -0.286 . . . . 0.0 113.231 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.462 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 75.4 m -140.61 -46.52 0.41 Allowed 'General case' 0 C--O 1.243 0.742 0 C-N-CA 122.748 0.419 . . . . 0.0 110.687 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.514 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.6 p-10 40.83 -167.94 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 125.117 1.367 . . . . 0.0 114.049 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.432 ' O ' HG22 ' A' ' 16' ' ' ILE . 21.3 tptt -47.43 -47.15 26.9 Favored 'General case' 0 C--N 1.353 0.76 0 C-N-CA 123.451 0.7 . . . . 0.0 111.343 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.425 ' H ' ' ND2' ' A' ' 11' ' ' ASN . . . -52.24 -44.9 58.04 Favored Glycine 0 C--N 1.35 1.338 0 O-C-N 124.209 0.943 . . . . 0.0 114.302 -179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.462 ' HB3' ' HB3' ' A' ' 10' ' ' SER . . . -89.8 -40.92 12.16 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 117.307 0.554 . . . . 0.0 111.83 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 11' ' ' ASN . 5.0 pt -65.84 -27.03 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 112.33 0.493 . . . . 0.0 112.33 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.432 HG22 ' O ' ' A' ' 12' ' ' LYS . 2.4 tp -87.25 -38.28 11.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 178.336 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -71.38 -36.77 63.05 Favored Glycine 0 C--N 1.346 1.128 0 CA-C-N 115.767 -0.651 . . . . 0.0 113.204 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.6 tp . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 117.985 -1.007 . . . . 0.0 111.615 -179.695 . . . . . . . . 0 0 . 1 stop_ save_